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Chlamydia trachomatis, the causative agent of trachoma and sexually transmitted 
infections, employs a type III secretion (T3S) system to deliver effector proteins into host 
epithelial cells to establish a replicative vacuole.  Although the temporal manner in which 
effectors are secreted is important for the proper manipulation of host cell functions, the 
mechanism remains a mystery. In this study, we provide several lines of evidence that T3S 
chaperones may impart coherence to effector secretion. In addition, we identified a new early 
T3S effector in Chlamydia. Aside from the phosphoprotein TARP, a Chlamydia effector that 
promotes actin re-arrangements, very few factors mediating bacterial entry and early inclusion 
establishment have been characterized. By defining proteins that associate with the three most 
abundant T3S chaperones, Slc1, Scc2 and Mcsc in invasive C. trachomatis elementary bodies 
(EB) by immunoprecipitation coupled with mass spectrometry, we identified Ct875, a new Slc1 
client protein and T3S effector, which we renamed TepP (Translocated early phosphoprotein).  
We provide evidence that T3S effectors form stable complexes with Scl1 in vitro and that Slc1 
enhances their T3S-dependent secretion in a heterologous Yersinia T3S system.  We 
demonstrate that TepP is translocated early during bacterial entry into epithelial cells and is 
phosphorylated at tyrosine residues by host kinases.  However, TepP phosphorylation occurs 
later than TARP, which together with the finding that Slc1 preferentially engages TARP in EBs 
leads us to postulate that these effectors are translocated into the host cell at different stages 
during C. trachomatis invasion. TepP co-immunoprecipitated with the scaffolding proteins CrkI-II 
during infection and Crk was recruited to nascent inclusions.  Importantly, C. trachomatis 
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mutants lacking TepP failed to recruit CrkI-II to inclusions, providing genetic confirmation of a 
direct role for this effector in the recruitment of a host factor.  Finally, endocervical epithelial 
cells infected with a tepP mutant showed altered expression of a subset of genes associated 
with innate immune responses and lack of C. trachomatis-induced morphological changes.  We 
propose a model wherein TepP acts downstream of TARP to recruit scaffolding proteins at entry 
sites to initiate and amplify signaling cascades important for the regulation of innate immune 
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1. Introduction  
1.1 Chlamydia trachomatis 
The gram-negative bacteria of family Chlamydiaceae are obligate intracellular bacteria 
that infect a broad spectrum of hosts ranging from humans and animals to free-living amoeba 
(Peters, Wilson, Myers, Timms, & Bavoil, 2007).  Within the family, Chlamydia pneumonia (or 
Chlamydophila pneumonia) and Chlamydia trachomatis are the two main species that infect 
humans.  Chlamydia pneumonia causes acute respiratory disease and has been linked 
seroepidemiologically to atherosclerosis and increased risk for myocardial infarction and 
coronary heart disease (Campbell & Kuo, 2004). Chlamydia trachomatis is the causative agent of 
trachoma, the leading cause of infectious blindness worldwide, and the major cause of bacterial 
sexually transmitted infections (STI) in the developed world (Low et al., 2012). Over 15 variants 
of C. trachomatis have been serologically defined to date and are associated with distinct 
human diseases (Schachter, 1999). Serovars A-C infect ocular tissues and cause conjunctivitis 
and blindness. Serovars D-K infect mucosal epithelial cells of the genital tract and can be 
transmitted sexually. The sequelae of this infection include pelvic inflammatory disease (PID), 
which can result in infertility in women, chronic pelvic pain, salpingitis, urethritis and ectopic 
pregnancy (Schachter, 1999). Serovars L1-L3 are associated with lymphogranuloma venereum, a 
systemic infection, which is also transmitted by sexual contact. Approximately 2.9 million cases 
of visual impairment and ~1.17 million cases of blindness are attributed to ocular infections by 
C. trachomatis (Pascolini & Mariotti, 2012).  Around 101 million cases of chlamydial infections 
are detected annually in the world, imposing a significant burden on the public health system 
(World Health Organization, 2011). Moreover, Chlamydia infection has been linked to an 
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increased risk of developing cervical carcinoma and transmission of HIV (Malhotra, Sood, 
Mukherjee, Muralidhar, & Bala, 2013). Although Chlamydia can be quickly detected by nucleic 
acid amplification tests and effectively treated with antibiotics such as azithromycin, doxycycline 
and tetracycline (Workowski, 2013), the rate of infection is increasing in the US (Centers for 
Disease Control and Prevention, 2013). There has not been a stable clinical isolate reported so 
far that is resistant to antibiotics (O'Neill et al., 2013), nevertheless, given the high frequency of 
re-infection and the massive usage of antibiotics, the emergence of this problem will be just a 
matter of time. Moreover, the immune response after Chlamydia exposure only provides partial 
protection against re-infection (Hu, Holland, & Burton, 2013). Therefore, it is necessary to 
develop new strategies to prevent the disease, such as a vaccine, which has been impeded by 
the poor understanding of the disease mechanism. This research will reveal some insights in 
Chlamydia pathogenesis.  
1.2 The C. trachomatis developmental cycle 
All Chlamydiaceae species have a biphasic life cycle that alternates between two unique 
developmental forms, the environmentally stable, infectious elementary body (EB)(size around 
0.25-0.3 µm), and the metabolically active, replicative, but non-infectious, reticulate body 
(RB)(size around 0.5 to 1 µm)(Fig. 1) (Moulder, 1991). Infection starts with the attachment of 
EBs to host cell membranes.  After inducing its own internalization, C. trachomatis rapidly 
modifies its endocytic vacuole, the so-called “inclusion”, to avoid fusion with endosomes and 
lysosomes (Heinzen, Scidmore, Rockey, & Hackstadt, 1996) and migrates to a perinuclear region 
of the cell (Clausen, Christiansen, Holst, & Birkelund, 1997; Grieshaber, Grieshaber, & Hackstadt, 
2003) where it undergoes a developmental transition to the RB form and proliferates.  Bacterial 
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replication occurs within the inclusion, and, mid-to-late in the infectious cycle, bacterial 
replication becomes asynchronous with RBs transitioning back to the EB form (for reviews, see 
(Abdelrahman & Belland, 2005; Moulder, 1991)).  In late stages of infection, the inclusion 
occupies the bulk of the host cell cytoplasmic space and EBs are released to infect adjacent cells 
by cell lysis or extrusion of the whole inclusion (Hybiske & Stephens, 2007).  
 
 
Figure 1: The developmental cycle of C. trachomatis serovar L2. 
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1.3 Modulation of host cellular functions by C. trachomatis effector 
proteins 
Though staying within the inclusion throughout the developmental cycle, Chlamydia is 
capable of re-programming diverse host cellular processes for its benefit to establish a 
replicative niche.  In the beginning of infection, Chlamydia induces host cellular cytoskeleton 
rearrangement to enhance its uptake. After entry, multiple host signaling pathways are hijacked 
to prevent apoptosis and evade innate immunity (Betts, Wolf, & Fields, 2009). Chlamydia also 
actively modifies the inclusion membrane and intercepts a subset of host vesicles containing 
sphingomyelin and cholesterol from the Golgi-apparatus to acquire nutrients and to escape from 
the endocytic pathway (Carabeo, Mead, & Hackstadt, 2003; Fields & Hackstadt, 2002; Hackstadt, 
Rockey, Heinzen, & Scidmore, 1996). These abilities are conferred by a collection of bacterial 
proteins, also known as effectors, that are delivered into the host cell at different stages of 
infection.  Some of these proteins specifically localize to the inclusion membrane. These 
inclusion membrane proteins, designated Incs, share a common structural feature of a 
predictable bi-lobed hydrophobic domain that spans around 40-60 a.a. (Bannantine, Griffiths, 
Viratyosin, Brown, & Rockey, 2000). However, other than Incs, most chlamydial effectors cannot 
be predicted from primary amino acid sequences and require experimental identification. The 
genetic intractability of Chlamydia has limited our information to these effectors. Most 
approaches to identify effectors have been indirect and relied on heterologous expression 
systems (Valdivia, 2008).  To date, only a handful of non-Inc effectors have been identified and, 
for most of them, their functions are unclear. 
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1.4 The C. trachomatis type III secretion system 
Many of these effectors, including Incs, are transported to the host cell cytoplasm by a 
protein translocation system, called the type III secretion (T3S) system. Pathogenic Gram-
negative bacteria, such as Yersinia, Salmonella, Escherichia coli, Pseudomonas syringae, 
Xanthomonas campestris and Shigella, commonly employ this system to manipulate target host 
cells (Mueller, Plano, & Fields, 2013). The system forms an injection-needle-like structure and 
spans three biological membranes: the inner and outer membranes of bacteria and host plasma 
membranes (during invasion), or inclusion membranes (post invasion). The targeted 
polypeptides are transported simultaneously across these membranes from bacterial cytosol to 
host cell cytoplasm. The whole apparatus is composed of around 25 proteins and can be 
subdivided into three components: a needle, a basal body and a C-ring compartment (Fig. 2) 
(Cornelis, 2006). The C-ring part of the apparatus associates with an ATPase (CdsN in Chlamydia) 
that presumably energizes the export process. In addition to the core components, a group of 




Figure 2: Chlamydia T3S system. The model is based on the Yersinia T3S system. 
 
Although a putative chlamydial T3S apparatus was observed as early as 1979 by electron 
microscopy (Gregory, Gardner, Byrne, & Moulder, 1979), its existence in Chlamydia was not 
confirmed until genome sequencing efforts identified homologs of genes encoding T3S 
components (Peters et al., 2007; Stephens et al., 1998). Unlike the T3S genes in other 
pathogenic Gram-negative bacteria, which are normally clustered in chromosomal Pathogenicity 
Islands and on plasmids, the chlamydial T3S genes are scattered into at least three distinct 
genomic clusters (Peters et al., 2007).  Also, the GC content of these regions are similar to the 
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rest of the genome, providing the lack of evidence for horizontal gene transfer (Peters et al., 
2007). This implies that chlamydial T3S might directly evolve from an ancestral T3S and is 
probably the closest to the primordial T3S apparatus (Kim, 2001).  Nevertheless, a recent review 
suggests that all T3S systems, including chlamydial T3S, are derived from flagella (Abby & Rocha, 
2012; Mueller et al., 2013). No matter the origin, phylogenetic analysis often sorts chlamydial 
T3S as a distinct family in comparison to other systems, implying its uniqueness (Buttner, 2012; 
Cornelis, 2006).  
 
Unfortunately, our understanding of how the chlamydial T3S system functions has been 
hampered by the lack of genetic tools and a complex biphasic developmental cycle. The 
functionality of the chlamydial T3S was not inferred until CopN, the putative T3S plug that limits 
premature secretion before activation, was shown to be secreted in a heterologous Yersinia T3S 
system (Fields & Hackstadt, 2000). Although indirect, this was the strongest evidence at that 
time supporting the hypothesis that Chlamydia uses T3S and brought attention to the possibility 
that T3S effectors helped reprogram the host cell. Although several basal components of the 
chlamydial T3S apparatus could be identified based on homology to those in other systems, 
some have diverged and the dispersion of chlamydial T3S genes in genome renders prediction 
difficult. Some missing components have been identified based on protein-protein interactions 
or by sophisticated additional bioinformatics analysis, followed by biochemical validation. For 
example, the chlamydial T3S translocators, CopB and CopD, were identified based on their 
interactions with specific chlamydial chaperones, Scc2 and Scc3 (Fields, Fischer, Mead, & 
Hackstadt, 2005; Spaeth, Chen, & Valdivia, 2009).  Similarly, CdsF, was suspected to be a needle 
component due to its small size and the gene location relative to other T3S components, and 
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validated biochemically (Betts, Twiggs, Sal, Wyrick, & Fields, 2008).  The identity of the needle 
tip protein remains controversial. Using computational structure prediction and biophysical 
analysis, Ct584 is suggested to be the T3S needle tip protein (Markham, Jaafar, Kemege, 
Middaugh, & Hefty, 2009). However, a structural study in Ct584 ortholog in C. pneumoniae, 
Cpn0803, as well as Ct584 in C. trachomatis, revealed no similarity to needle tip protein, 
although Cpn0803 shows interaction with multiple T3S components, including CdsN (ATPase), 
CdsQ (C-ring component) and CdsF and some host lipids, implying association with T3S system 
and host membrane (Barta et al., 2013; Stone et al., 2012).  Recently, one group suggested that 
Ct584 functions as a T3S chaperone (Pais, Milho, Almeida, & Mota, 2013), leaving the role of 
Ct584 an open question.  
  
Although the overall structure, as well as the secretion mechanism, is likely conserved, 
the chlamydial T3S system contains some unique features that differentiate it from other T3S 
systems (Betts-Hampikian & Fields, 2010). For example, C. pneumoniae CdsD, a YscD homolog of 
the inner membrane ring protein, is phosphorylated and represents the first example of T3S 
apparatus component that undergo phosphorylation (Johnson & Mahony, 2007), yet the 
function of this phosphorylation is still unclear. In addition, fractionation study indicates that 
CdsD may not be an integral membrane protein but a peripheral membrane protein with a high 
hydrophilicity (Johnson, Stone, & Mahony, 2008), rendering it difficult to define the role of CdsD. 
In addition, CdsC, homolog of outer membrane protein secretin, contains a unique hydrophilic 
domain at the N-terminus and lacks regions required for oligomerization and membrane 
association that are present in other homologs (Betts-Hampikian & Fields, 2010). Interestingly, 
unlike other known T3S system, Chlamydia contains two sets of translocator proteins, 
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CopB/CopD and CopB2/CopD2. Biochemical and localization analysis implies that these two sets 
of translocator proteins may function differently during Chlamydia infection (Chellas-Gery, Wolf, 
Tisoncik, Hackstadt, & Fields, 2011). 
 
The importance of the T3S system in Chlamydia pathogenesis was inferred by small 
molecule inhibitors that were first identified in a screen for inhibitors of the Yersinia T3S system. 
These inhibitors either partially inhibited or had no effect on Chlamydia entry. But all of them 
impacted bacterial replication and RB to EB transition and reduced the yield of infectious 
progeny (Muschiol et al., 2006; Muschiol, Normark, Henriques-Normark, & Subtil, 2009; Wolf et 
al., 2006). The mechanism of inhibition, nevertheless, is still questionable. The translocation of 
many known T3S effectors, such as IncG, IncA, Tarp, and CADD, were affected (Muschiol et al., 
2006; Wolf et al., 2006). However, these compounds have a minimal effect on bacterial entry, 
which is assumed to rely heavily on T3S effector translocation. Also, adding iron reversed the 
defect induced by some inhibitors and some gene transcriptions were affected by adding these 
inhibitors (Slepenkin et al., 2007; Wolf et al., 2006). More importantly, mutation in hemG, a 
protoporphyrinogen oxidase that catalyzes a central step in heme biosynthesis, confers resistant 
to these compounds (Engstrom et al., 2013). Together, these imply that the observed defects 
might be contributed from multiple factors, not only inhibition of T3S system. 
 
Proteins destined for T3S contain a secretion signal located within the N terminal ~20-30 
amino acids (Galan & Wolf-Watz, 2006). Although two algorithms are now available to predict 
T3S substrates (Arnold et al., 2009; Lower & Schneider, 2009), most potential T3S effector 
proteins in Chlamydia were identified through expression and secretion in heterologous 
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bacterial systems (Ho & Starnbach, 2005; Subtil et al., 2005). These findings predict that about 
5~8% of the chlamydial genome encodes potential substrates of T3S (Valdivia, 2008). Since 
Chlamydia reprograms host cellular functions sequentially at different stages of development to 
create a suitable replicative niche, these effectors may be secreted in a defined sequence to 
achieve different tasks. This kind of hierarchical secretion has been observed in other T3S 
systems. For example, in Salmonella typhimurium, effectors SipA, SopE and SptP all are pre-
formed in the bacterial cytosol but SipA and SopE are injected earlier than SptP (Winnen et al., 
2008). Since SipA and SopE, and SptP have opposing effects on remodeling actin cytoskeleton 
(Zhou & Galan, 2001), this ordered secretion ensures effectors exert their functions at the right 
time. The mechanism through which this is achieved, however, is still unclear. The T3S 
apparatus-associated ATPase protein may play a role in cargo recognition by studies in Yersinia 
and Salmonella (Akeda & Galan, 2005; Sorg, Blaylock, & Schneewind, 2006). Nevertheless, it is 
unknown if this functionality is conserved in Chlamydia. In addition, accessory proteins such as 
the chaperones of cognate effectors might confer another layer of substrate specificity that 
helps determine the order of secretion (Birtalan, Phillips, & Ghosh, 2002; Boyd, Lambermont, & 
Cornelis, 2000). More studies are required to support these hypotheses. 
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2. Mcsc, a multiple cargo secretion chaperone, binds to its cargos 
with different affinities  
2.1 Introduction 
2.1.1 Class I T3S Chaperones 
Effectors destined for T3S possess a secretion signal within the N terminal 20-30 amino 
acids (a.a.) that is often sufficient for secretion (Galan & Wolf-Watz, 2006). However, many 
effectors require ancillary chaperone proteins for efficient translocation into target cells. These 
class I chaperones are customized for their cognate effectors; the secreted effector generally 
wraps around the chaperone dimer using the secondary structural elements of the first 50-100 
a.a. while the C-terminal regions remain folded (Lilic, Vujanac, & Stebbins, 2006; Parsot, 
Hamiaux, & Page, 2003). Depending on the number of effectors with which they can associate, 
class I chaperones are further divided into class IA and IB (Thomas, Ma, Prasad, & Rafuse, 2012). 
Class IA chaperones are specific for single effectors and the genes encoding the chaperone-
effector pair are often adjacent. Class IB chaperones associate with more than one effector and 
the genes encoding these chaperones are often unlinked from that of its cognate cargos.  Many 
common features are shared by class I chaperones, including small size (15~20 kDa), acidic 
isoelectric points (pI), a stable homodimeric conformation, and an ATP-independent chaperone 
function (Thomas et al., 2012). Structurally, class I chaperones contain a basic core consisting of 
three α-helices and five β-sheets (Izore, Job, & Dessen, 2011); however, the degree of 
conservation at the amino acid level is limited, making the identification of new T3S chaperones 
difficult. 
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2.1.2 Inclusion membrane proteins 
After entering into the host cell, Chlamydia replicates inside a membrane-bound vacuole 
termed an inclusion. The inclusion membranes are derived from host cell membranes and then 
actively and continuously modified by Chlamydia as infection proceeds. The inclusion fuses with 
Golgi-derived vesicles containing sphingomyelin and cholesterol (Carabeo et al., 2003; Hackstadt 
et al., 1996), and a group of effectors are secreted by the T3S system and incorporated into the 
inclusion membrane via a still unclear mechanism. These inclusion membrane proteins, 
designated Incs, share a common structural feature: a bi-lobed hydrophobic domain that can be 
easily observed in a hydropathy plot and typically spans around 40-60 a.a. (Bannantine et al., 
2000). This domain is usually at the N-terminus but can also be present at the C-terminus, and 
some Incs have multiple bi-lobed hydrophobic domains (Toh, Miura, Shirai, & Hattori, 2003). 
Around 50 Incs were predicted to be encoded in C. trachomatis in silico and around 40 of them 
were verified experimentally (Li et al., 2008). Since these Inc proteins are localized at the host-
pathogen interface, they are likely central regulators of host functions and play vital roles in 
Chlamydia pathogenesis. However, due to the genetic intractability of Chlamydia, only a few of 
these Incs have known functions. For example, IncA is involved in homotypic fusion of inclusions 
and mediates the recruitment of SNARE proteins to inclusion membranes (Delevoye et al., 
2008). In the same study, the authors also found that Ct813 is another Inc that interacts with 
SNARE proteins, Vamp7 and Vamp8. In addition, IncG, Ct228, Ct229 and IncD interact with 14-3-
3β, MYPT1 (a subunit of myosin phosphatase), Rab4, and the lipid transporter CERT, respectively 
(Derre, Swiss, & Agaisse, 2011; Lutter, Barger, Nair, & Hackstadt, 2013; Rzomp, Moorhead, & 
Scidmore, 2006; Scidmore & Hackstadt, 2001). More studies are ongoing to uncover the function 
of these membrane proteins.  
 13 
2.1.3 Multiple Cargo Secretion Chaperone (Mcsc) 
Mcsc (Ct260), which does not share any obvious sequence homology with known T3S 
chaperones, was first revealed as a potential T3S chaperone experimentally in a yeast two-
hybrid screen. The authors unbiasedly screened the interactions between 208 Chlamydia-
specific conserved hypothetical open reading frames (ORFs) and found that Mcsc interacted 
with itself, a T3S component protein, and multiple Incs, including Cap1 (Ct529), Ct225 and Ct618 
(Spaeth et al., 2009). Mcsc has several features that fit characteristic of T3S chaperone: it has a 
small molecular weight (18.8 kDa), an acidic pI (4.6), and it forms a dimer. Its interactions with 
Cap1 and Ct618 help stabilize their expression in E. coli; thus Mcsc was classified as a bona fide 
Class IB T3S chaperone (Spaeth et al., 2009). Cap1, or class I accessible protein-1, was originally 
identified because it can be recognized by CD8+ cells, and it was shown to localize to the 
inclusion membrane (Fling et al., 2001). Similarly, Ct618 and Ct225 were shown to localize to the 
inclusion membrane, as revealed by immunofluorescence staining (Li et al., 2008; Sisko, Spaeth, 
Kumar, & Valdivia, 2006). The actual functions of these Incs remain unknown. Interestingly, 
expressing the cytosolic domains of Cap1 and Ct618 in yeast caused rapid growth arrest, 
implying that these two proteins may interfere with important cellular functions (Sisko et al., 
2006). 
2.1.4 Hierarchical protein secretion in T3S system 
Hierarchical secretion has long been observed in T3S systems but how it is regulated is 
still a puzzle. Pathogens that employ T3S system usually contains a set of substrates ready to be 
secreted upon activation. For example, Yersinia has at least five Yops (Yersinia outer protein) 
that are secreted by the T3S system (Trosky, Liverman, & Orth, 2008) and in enteropathogenic 
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Escherichia coli (EPEC), at least 27 T3S effectors were found (Wong et al., 2011). In the case of 
Salmonella typhimurium, it is observed that SipA, SopE and SptP are all pre-formed effectors in 
bacterial cytosol but SipA and SopE are injected earlier than SptP (Winnen et al., 2008).  Since 
several effector proteins are present at any one time, the T3S apparatus may have a mechanism 
to recognize and transport target proteins in the right time and right order. The mechanism 
through which this is achieved is still under debate. T3S substrates contain a secretion signal at 
the N-terminus; nevertheless, it is still undetermined how the signals are recognized by the 
system. On the side of the T3S apparatus, it is indicated that the T3S-apparatus-associated 
ATPase may play a role in cargo recognition. A study in Yersinia shows that YscN, the T3S-
apparatus-associated ATPase, binds to the T3S secretion signal of YopR (Sorg, Blaylock et al. 
2006). In addition, the Salmonella ATPase InvC has been shown to interact with SicP-SptP, a 
chaperone-effector complex, and induce dissociation of chaperone from effector and unfolding 
of the secreted effector protein in an ATP-dependent manner (Akeda and Galan 2005). These 
results suggest that ATPase may recognize the secretion signal and energize the transport 
process. Additional T3S components may contribute to recognizing secreted cargos and bringing 
them in proximity to the ATPase for secretion. The C-ring component of T3S apparatus may 
perform this duty. This is supported by the study showing that spa33, the Shigella C-ring 
component protein, interacts with multiple effectors (Morita-Ishihara et al., 2006). Also, in the 
plant pathogen Xanthomonas campestris pv. vesicatoria, the C-ring component HrcQ binds to 
HrcN (ATPase) and several secreted T3S substrates (Lorenz, Hausner, & Buttner, 2012). In 
Chlamydia, the C. pneumonia C-ring component CdsQ interacts with CdsN (ATPase) and the C. 
trachomatis ortholog interacts with Mcsc alone and Mcsc in complex with effectors Cap1 or 
Ct618 (Spaeth et al., 2009; Stone, Johnson, Bulir, Gilchrist, & Mahony, 2008). However, whether 
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this constitutes a general recognition mechanism for secreted effectors by T3S machines is not 
clear. 
 
From the side of the secreted cargo, accessory proteins such as the chaperones of 
cognate effectors might confer another layer of substrate specificity to help determine the order 
of secretion (Cornelis, 2006). In agreement with this, YopE, a Yersinia T3S effector lacking a SycE 
chaperone binding site, is secreted in the absence of other T3S effectors. However, YopE 
secretion is severely impaired when other effectors are allowed to compete with it, indicating 
that additional secretion signals are either unmasked or conferred by the T3S chaperone (Boyd 
et al., 2000). Even for effectors sharing the same chaperone, there seems to be a defined order 
of secretion. For instance, CesT from EPEC binds to at least 10 T3S effectors, but one of the 
cargos, Tir, is secreted first, and Tir secretion is important for secretion of the remaining 
effectors (Thomas, Deng, Baker, Puente, & Finlay, 2007). How a chaperone can be involved in 
this regulation remains to be elucidated. 
 
In this study, we focus on the interactions between Mcsc and its cargos, Cap1, Ct225 and 
Ct618. We mapped the chaperone binding regions in these effectors to around fifty a.a. and 
observed a distinct binding affinity of these peptides to Mcsc. The order of binding affinity was 
inversely correlated to the transcriptional timing of genes encoding these proteins, which 
suggests that secretion hierarchy may be partially imparted by chaperone-binding affinity. In 
addition, we employed newly developed DNA transformation techniques in Chlamydia (Wang et 
al., 2011) to demonstrate that Mcsc binding is important for the stability and secretion for Cap1 
in vivo.  
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2.2 Materials and Methods 
2.2.1 Bacterial strains, cell lines, and reagents 
HeLa cell and Vero cells were maintained in Dulbecco’s minimal essential medium 
(DMEM) (Sigma-Aldrich, St. Louis, Missouri, USA) supplemented with 10% fetal bovine serum 
(Mediatech, Manassas, Virginia, USA) at 37°C, 5% CO2.  Infections were synchronized by adding 
EBs to HeLa monolayers with specified multiplicity of infection (MOI) prior to centrifugation at 
3000 rpm for 30 min at 10°C. All affinity-tagged recombinant proteins were expressed in E. coli 
BL21 DE3 and induced with 0.5 mM IPTG for 3 hr at 37°C. 
2.2.2 Generation of antibodies  
GST-Mcsc and GST-Ct618 (a.a.1-96) were expressed in E. coli and purified with 
glutathione-coated Sepharose 4-Fast Flow beads (GE Healthcare).  Recombinant proteins was 
eluted with 20 mM reduced glutathione in PBS (pH 7.4) and used to immunize female White 
New Zealand rabbits (5~6 lbs) (Robinson Services, Inc.).  Antisera were depleted of anti-GST 
antibodies first and affinity purified over a GST-Mcsc or GST-Ct618-crosslinked column.  Bound 
antibodies were eluted with 0.2 M Glycine (pH 2.5) and neutralized with 1 M K2HPO4. The 
resulting antibodies were then dialyzed in PBS twice and once in PBS containing 1% BSA, 5% 
glycerol and 10 mM NaN3 and stored in -80 °C.   
2.2.3 Immunoblot analysis 
For immunoblot analysis, protein samples were separated by SDS-PAGE, transferred to 
0.45 µm nitrocellulose membranes (Bio-Rad, Berkeley, CA, USA) and blocked in 3% non-fat 
powder milk in TBST (50 mM Tris-Base, 150 mM NaCl, 0.2% Tween-20 pH 7.4) for 20 min at RT.  
Membranes were incubated with primary antibody diluted in 3% milk-TBST overnight, followed 
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by three times of wash with TBST and incubation with secondary antibody conjugated to 
horseradish peroxidase for 30 min. The signals were detected by chemiluminescence 
(PerkinElmer, Waltham, MA, USA) and autoradiography film (Genesee, San Diego, CA, USA).  For 
quantitative immunoblot, membranes were incubated with dye-conjugated secondary 
antibodies, IRDye 800CW Goat anti-rabbit antibodies and IRDye 680LT Goat anti-mouse 
antibodies (LI-COR, Lincoln, Nebraska, USA). Images were acquired and signals were quantified 
using an Odyssey Fc Imager (LI-COR, Lincoln, Nebraska, USA). Primary antibodies include anti-
Tarp (1:1000) (generated in our laboratory), MOMP (1:2000) (gift from Dr. K. Fields), Cap1 
(1:1000) (gift from Dr. A. Subtil, Pasteur Institute), actin (1:1000) (Sigma-Aldrich), GSK-3β 
(1:1000) (Cell Signaling #9325) and phospho-GSK-3β (Ser9) (1:500) (Cell Signaling #9336) (Cell 
Signaling Technology, MA, USA). 
2.2.4 Yeast Two Hybrid (Y2H) 
Different truncation forms of Cap1 (Ct529) and Ct618 were PCR amplified from a 
previously established chlamydial open reading frame (ORF) library (Spaeth et al., 2009) with 
long tail primers containing homologous regions of yeast vector. Cloning was achieved by 
transforming both PCR products and digested Y2H vectors, pGAD424 or pGBT9, and ssDNA into 
yeast by the lithium acetate method (Brown, 1998). Successful homologous recombinations 
were selected by growing yeast on synthetic complete (SC) medium plates lacking either leucine 
(Leu) or tryptophan (Trp) for pGAD424 or pGBT9, respectively. Individual yeast colonies were 
then selected, inoculated into liquid culture, and grown overnight. Plasmids were extracted by 
phenol-chloroform and re-transformed into E. coli. Constructs were then purified from E. coli 
and verified by sequencing. Mcsc was cloned into pGAD424 vector, which contains the GAL4 
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activation domain; tested proteins were cloned into pGBT9, which contains the GAL4 DNA 
binding domain. To perform Y2H, reciprocal constructs were transformed into Y2H reporter 
strains, PJ69-4a (MATα) or AH109 (MATa), separately, and selected on appropriate SC plates. 
Different mating types of yeasts were mated in YPD rich media for two days, followed by 
selection in SC medium lacking both Leu and Trp. The resulting diploids were then plated on SC 
media plates lacking either Leu/Trp, histidine (His) or adenine (Ade). Growth on –His and –Ade 
indicated positive interaction. 
2.2.5 Chlamydia transformation 
Seed preparation. Confluent Vero cells in a T75 flask were infected with Chlamydia 
trachomatis serovar L2/434/Bu with an MOI of 10 for 40-44 hr. To collect bacteria, cells were 
first washed twice with 1x PBS and then scrapped in 1 mL deionized water, followed by passing 
through a 27G1/2 needle more than 5 times to help lysis. Lysate was centrifuged at 500xg for 5 
min at 4°C to get rid of cell debris. Appropriate amount of 5X SPG was added to supernatant to 
reach concentration of 1X. Seeds were titered, aliquoted, and stored at -80°C. 
 
Transformation. The transformation was performed as previously described (Wang et 
al., 2011) with some modifications. Briefly, a volume of Chlamydia seed containing around 108 
IFUs was incubated with 6 µg plasmid or without plasmid (mock-transformed control) in 200 µl 
transformation buffer (10 mM Tris pH 7.4 in 50 mM CaCl2) for 30 min at room temperature. 
Vero cells were trypsinized and pelleted down at 500xg for 5 min. The supernatant was 
discarded and the cells were re-suspended in 5 mL transformation buffer and pelleted down 
again. The supernatant was discarded and the cells were re-suspended in 500 µL transformation 
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buffer and counted in the hemocytometer with dilution of 1/50 to 1/100. Around 4x106 cells 
were transferred to a new microtube and the volume was adjusted to 200 µL with 
transformation buffer. Two hundred µl transformed seeds were mixed with 200 µL CaCl2-treated 
cells and incubated for 20 min at room temperature and the mixture was shaken every 5 min to 
prevent sedimentation of cells. In the meantime, 6-well plates with 3 mL fresh media in each 
well were prepared and 100 µL mixture was added into each well and the plates were spun at 
3000 rpm for 30 min to increase the efficiency of infection. After centrifugation, the plate was 
shifted to 37°C incubator and incubated for around 40 hr. This is P0. New confluent 6-well plates 
with Vero cells were prepared the second day. On day 3, bacteria were collected as described in 
seed preparation and ~1/8 to 1/4 volume of collected bacteria was added to a new 6-well plate 
with confluent cells in media supplemented with 500 ng/mL cycloheximide and 1U of penicillin 
G and the plates were spun at 3000 rpm for 30 min. The rest of the P0 was stored in -80°C. After 
centrifugation, the plates were shifted to 37°C incubator and incubated for more than 40 hr. 
This is P1. At this stage, a lot of persistent inclusions would be observed. New confluent 6-well 
plates with Vero cells were prepared on Day 4. Bacteria were collected as described above on 
day 5 and all collected bacteria were added to a new plate with confluent Vero cells. This is P2. 
Bacteria were continuously passed to new cells every three to four days in the presence of 1U 
penicillin G until normal inclusion was observed. In mocked transformed Chlamydia, there 
should be no normal inclusion under penicillin G selection. Penicillin G concentration was 
increased to 10 U when expending and enriching transformed Chlamydia. 
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2.2.6 in vivo secretion assay 
Genes encoding the cytoplasmic region of Cap1 (1-225 a.a.) and Ct618 (1-189 a.a.) were 
PCR amplified and cloned into a C. trachomatis-E. coli shuttle plasmid with a IncD promoter and 
a C-terminal Glycogen Synthase Kinase (GSK) tag (modified from p2TK2-SW2 (Agaisse & Derre, 
2013) by Dr. Jeff Barker and Dr. Joe Dan Dunn). Cap1 H188A and H188D and Ct618 H156A and 
H156D were obtained using site-directed mutagenesis with QuickChange Kit (Agilent 
Technologies, Santa Clara, CA) as instructed by the manufacturer. Constructs were transformed 
into C. trachomatis serovar L2/434/Bu as mentioned above. Selected transformants were 
enriched, expanded and titered. For secretion assays, confluent HeLa cells in a 24-well plate 
were infected with Chlamydia transformed with different constructs at an MOI of 200 and 
collected at indicated time points. Samples were subjected to immunoblot analysis and probed 
with anti-GSK and anti-phospho-GSK antibodies. Images were acquired using LI-COR Odyssey 
Imaging system and signals were quantified using the LI-COR Odyssey software. Efficiency of 
secretion was determined by dividing phospho-GSK signal by GSK signal. 
2.3 Results 
2.3.1 Cap1 protein is expressed earlier than Ct618 during Chlamydia infection 
Since multiple inclusion membrane proteins interact with the same chaperone, we first 
wanted to determine the timing of their expression in Chlamydia. Although Mcsc is one of the 
most abundant T3S chaperones in EBs, neither Cap1 nor Ct618 were detected in an EB proteome 
study (Saka et al., 2011). Consistent with this observation, the mRNAs for Cap1, Ct225 and Ct618 
were detected 1, 3, 8 hour post infection (hpi), respectively, in a comprehensive transcriptional 
analysis of Chlamydia infection (Belland et al., 2003), which suggests that these proteins are 
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expressed post bacterial entry. However, the presence of mRNA does not necessary mean that 
the protein is expressed. To address this question, we infected HeLa cells with Chlamydia 
serovar L2 at an MOI of 50 and collected the whole cell lysates at 2, 4, 6, 8 and 12 hpi and 
analyzed the sample by immunoblot with anti-Cap1 and Ct618 antibodies. Because the 
antibodies we raised against Ct225 did not recognize any specific band during infection, we did 
not include Ct225 in this study. We detected Cap1 protein as early as 1 hpi; whereas Ct618 
protein was not detected until 12 hpi (Figure 3). Overall, the immunoblot results are in good 
agreement with the transcription data. 
 
Figure 3: Cap1 is expressed earlier than Ct618 during Chlamydia infection. Confluent HeLa cells 
were infected with C. trachomatis L2 at an MOI of 50. Samples were collected at indicated time 
points and analyzed by immunoblot with antibodies against Ct618, Cap1, RopB (loading control 
for bacteria) and Actin (loading control for HeLa cells). Cap1 was detected as early as at 2 hpi; 
whereas Ct618 was detected at 12 hpi. C - HeLa cells only. 
  
2.3.2 Mapping interaction regions between Mcsc and its cargos by Y2H 
Since Mcsc binds to multiple cargos, we wanted to determine how each Inc protein 
interacts with Mcsc. To elucidate their binding interfaces, we collaborated with Dr. Pei Zhou 
(Department of Biochemistry, Duke University Medical Center) to determine the structure of 
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Mcsc with and without its cargos. However, expressing the cytoplasmic domains of both Cap1 
and Ct618 in E. coli is toxic and produces a very low protein yield (data not shown). Therefore, 
we decided to first map the Mcsc-binding regions in Cap1 and Ct618. In our previous work, the 
binding domains for Cap1 and Ct618 were mapped to 100 to 298 a.a. and 100 to 214 a.a., 
respectively (Spaeth et al., 2009). To narrow down the minimal region, different truncated forms 
of Cap1 and Ct618 were cloned into the Y2H vector pGBT9 (vector containing GAL4 DNA-Binding 
Domain) and transformed into a Y2H reporter strain. The vector pGAD424 (vector containing 
GAL4 Activation Domain) that contains wild type Mcsc was transformed into another Y2H 
reporter strain of the opposite mating type. After mating, the resulting diploids were selected in 
medium lacking leucine (L) and tryptophan (T) and positive interactions were assessed by 
growth on plates lacking histidine (H) or adenine (A).  The results show that the Mcsc-binding 
domain for Cap1 is within 176 to 224 a.a., and for Ct618, it is between 140 to 193 a.a. (Fig. 4A). 
To our surprise, this binding region is quite different from the usual chaperone-binding region, 
which is within the first ~50-100 a.a. of effector protein (Lilic et al., 2006). This implies that the 
interaction might not follow the canonical rules of effector-chaperone interactions. Additionally, 
these two regions have two similar properties. First, both are located adjacent to the bi-lobed 
hydrophobic domain, a common motif found in all Incs (Fig. 4B). Second, these regions are 
predicted to form two alpha helices by Network Protein Sequence Analysis (http://npsa-
pbil.ibcp.fr/). Whether these patterns are coincidence or are conserved among all Mcsc effectors 
substrates remains to be determined. Because the original Y2H construct for Ct225 had already 
narrowed down the binding region to 69 to 122 a.a. after removal of the bi-lobed hydrophobic 
domain, we did not include Ct225 in this Y2H study. Nevertheless, the binding region for Ct225 is 
also adjacent to the bi-lobed hydrophobic domain, suggesting that binding to Mcsc might help 
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mask the bi-lobed hydrophobic domains of these Incs, which are often toxic to bacteria. These 
Mcsc binding domains were further fused to either GB3 protein tag (Ct618 and Ct225) or GB1 
protein tag (Cap1), depending on their pI, to increase their stability and solubility (gift from Dr. 
P. Zhou). These fusion proteins expressed well in E. coli, and all fused peptides form complexes 





Figure 4: The central regions of Ct618 and Cap1 mediate binding to Mcsc. The Mcsc binding 
domains of Ct618 and Cap1 were mapped by Y2H. Different truncated forms of Cap1 and Ct618 
were cloned into pGBT9 (GAL4/DNA binding domain) and transformed into Y2H reporter strain 
to test their interactions with Mcsc, which was fused to GAL4/activation domain. A) Positive 
interactions were assessed by activation of GAL4-dependent HIS3 and ADE2 reporter genes and 
growth of yeast in media lacking histidine (-H) or adenine (-A). Growth on media lacking both 
tryptophan (-T) and leucine (-L) are shown as controls for maintenance of the Y2H vectors. B) 
Cartoon schema of Mcsc binding regions in Ct618 and Cap1. Both regions are adjacent to the 
large hydrophobic region mediating insertion into the inclusion membrane and are mainly α-
helices. 
 
2.3.3 Chaperone binding is important for the stability of recombinant Cap1 in 
vivo 
The T3S chaperones usually help stabilize or enhance the secretion of their cargo. Our 
previous study demonstrated that mutating the predicted effector binding sites in Mcsc reduced 
the protein expression levels of both Cap1 and Ct618 in an E.coli expression system using a bi-
cistronic vector (Spaeth et al., 2009). However, whether this is the case in Chlamydia is unclear. 
New advances in genetic manipulation (Wang et al., 2011) allowed us to ectopically express 
proteins in Chlamydia. To examine the importance of Mcsc binding in the stability of its cargos in 
the natural environment, we ectopically expressed these proteins in Chlamydia and traced the 
expression level of these proteins after disrupting chaperone interaction. Nevertheless, this 
 25 
approach would require us knowing the residues in effectors that bind to Mcsc. As mentioned 
above, we have mapped the Mcsc binding regions for all three Incs, Cap1, Ct225 and Ct618. By 
collaborating with Dr. Pei Zhou and Dr. Chul-Jin Lee in the Biochemistry department, we now 
have a solved structure of Mcsc both in apo form and in complex with the cargo peptides, Ct618 
and Cap1, by X-ray crystallography. The attempt to solve the structure of the Mcsc/Ct225 
peptide complex, however, is still in progress.  
 
The structure of the Mcsc apo form, like other T3S chaperone, is composed of three α-
helices and five β-sheets. By mutagenesis analysis, Dr. Chul-Jin Lee determined that the histidine 
residue at amino acid 156 in Ct618 is important for binding as it made key contacts with Mcsc 
and because mutating this residue to alanine (A) reduced the binding affinity by more than 200-
fold and mutating to aspartic acid (D) completely abolished the interaction (Table 1) (Dr. Chul-Jin 
Lee, unpublished data). Similarly, mutating the respective histidine in Cap1 at a.a. 188 disrupted 
the binding between Cap1 peptide and Mcsc. The interacting residue in Ct225, however, is still 
undetermined because there is no histidine in the corresponding position. We applied this 
information to our system to test whether disrupting chaperone binding affects effector 
stability. We first cloned the cytoplasmic region of Cap1 and Ct618 in a C. trachomatis-E. coli 
shuttle plasmid under the control of the IncD promoter with a Glycogen Synthase Kinase (GSK) 
tag fused to the C-terminus of these proteins. Finally, we introduced H188A and H188D 
mutations to the Cap1-GSK construct and H156A and H156D mutations to the Ct618-GSK 
construct. These six constructs were than transformed into C. trachomatis serovar L2/434/Bu 
individually and selected under penicillin G for several passages. To assess the steady-state 
levels of these recombinant proteins, HeLa cells were infected with Chlamydia expressing these 
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various constructs at an MOI of 200 and cell lysates were collected at indicated time points. 
Collected samples were subjected to quantitative immunoblot analysis with antibodies against 
GSK to determine the total levels of recombinant protein expressed and MOMP, which served as 
a control for bacteria loads. The signals were quantified using a LI-COR Odyssey imaging system 
and software. GSK signals were first normalized to the MOMP signal and compared to wild type 
recombinant protein, which was set to be 100%. The protein expression level of WT Ct618 is 
much lower than Cap1 and was barely detected at later time points (> 24 h). Hence, Ct618 was 
not studied further. The results showed that all mutations decreased the stability of 
recombinant Cap1.  This level of decrease was inversely correlated with the binding affinity to 
Mcsc and time post infection, indicating that Mcsc binding is important for the stability of 
recombinant Cap1 in Chlamydia (Fig. 5). 
 
Table 1: Binding affinity between Mcsc and its cargos by isothermal titration 
calorimetry (ITC) (Dr. Chul-Jin Lee, unpublished data). 
Ligand 
Mcsc 












 -  - 
 
  *no appropriate binding isotherm obtained for data fitting. 




Figure 5: Mcsc binding is important for the stability of recombinant Cap1 in C. trachomatis. WT 
Cap1 and mutant constructs were transformed into C. trachomatis L2/434/Bu. Successful 
transformants were used to infect HeLa cells at an MOI of 200 and cells lysates were collected at 
10 and 20 hpi. Samples were subjected to quantitative immunoblot analysis with antibodies 
against GSK and MOMP. GSK signals were first normalized to the MOMP signal and then 
compared to WT Cap1 (100%). Results shown were mean and standard deviation from three 
independent biological replicates.  
 
2.3.4 Chaperone binding enhances recombinant Cap1 secretion in vivo 
Glycogen synthase kinase (GSK) is a tag not only good for monitoring protein expression 
but also secretion. This 13 a.a. peptide tag is derived from the human GSK-3β kinase and is 
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phosphorylated at serine residue by a eukaryotic host kinase (Garcia et al., 2006). Since this tag 
can only be recognized by eukaryotic kinases, only the protein translocated into host cell 
cytoplasm is phosphorylated. This provides us a means to examine protein secretion in 
Chlamydia, as has been shown for T3S and T4S systems in other bacteria (Garcia et al., 2006). 
Based on this assumption, we infected HeLa cells with Chlamydia transformants described in the 
previous section and collected samples at indicated time points and analyzed samples using 
quantitative immunoblot. In addition to probing with anti-GSK antibody, we also probed the 
immunoblots with anti-phospho-GSK antibody and determined the ratio of phospho-GSK/GSK 
signals, which gives a direct degree of secretion. Because the phospho-GSK signals for Ct618 and 
H188D Cap1 were below the detection limit, we were unable to quantify the ratio. Nevertheless, 
we observed a 2 fold reduction in the ratio of phospho-GSK/GSK signal in H188A Cap1 compared 
to wild type Cap1, indicating that Mcsc binding not only stabilizes Cap1, but also enhances its 
secretion in vivo (Fig. 6). 
 
Figure 6: Mcsc binding enhances the secretion of recombinant Cap1 in vivo. WT Cap1 and point 
mutant constructs were transformed into C. trachomatis L2/434/Bu. Successful transformants 
were used to infect HeLa cells at an MOI of 200 and cells lysates were collected at 10 hpi. 
Samples were subjected to quantitative immunoblot analysis with antibodies against GSK, p-GSK 
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and MOMP. Phospho-GSK signal was divided by GSK signal and then compared to WT Cap1 




Figure 7: Model of a hierarchical secretion imparted by T3S Chaperone Mcsc during Chlamydia 
Infection. Mcsc, a class IB type III secretion chaperone in C. trachomatis, binds to three inclusion 
membrane proteins, Cap1, Ct225 and Ct618. Genes encoding these three proteins are 
transcribed and translated at different times post-infection. At early stage of infection, Cap1 is 
expressed and immediately secreted by T3S system because there is no substrate competition. 
Later, Ct225 is expressed and starts to compete with Cap1 for Mcsc. Since Ct225 has a higher 
affinity to Mcsc, Mcsc preferentially binds to Ct225 over Cap1 and the T3S system starts to 
secret Ct225. Similarly, when Ct618 is expressed, even though both Cap1 and Ct225 are present, 
because it has the highest affinity toward Mcsc among them, it binds to Mcsc and is secreted by 
the T3S system. hpi-hour post infection. 
 
2.4 Discussion 
New genetic tools have allowed us to examine the function of Mcsc in Chlamydia, which 
previously could only be tested in a heterologous system. By transforming with wild type and 
mutant effectors that are altered in their ability to bind to their chaperone, we demonstrated 
that Mcsc helps stabilize and enhance the secretion of at least one of its cargos, Cap1, in C. 
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trachomatis. With this technique, we can now start to ask questions such as what proteins are 
secreted, how the substrates are recognized and even develop new tools to knockdown target 
genes specifically. 
 
T3S chaperones have been suggested to play a role in determining secretion hierarchy 
(Cornelis, 2006). Studies in the Yersinia SycE-YopE chaperone-effector system suggests that the 
complex might form a 3D secretion signal that can be recognized by T3S apparatus preferentially 
over effector alone and may contribute to the temporal order of secretion (Birtalan et al., 2002; 
Boyd et al., 2000). This scenario is not only observed in class 1A chaperone, which binds to one 
cargo, but also in class IB chaperone. Indeed, a real-time analysis of CesT-dependent traslocation 
revealed a distinct order in the translocation of multiple EPEC effectors, with Tir protein being 
the first, indicating a translocation hierarchy is established within effectors sharing the same 
chaperone (Mills, Baruch, Charpentier, Kobi, & Rosenshine, 2008). Since these effectors all bind 
to the same chaperone, an additional layer of regulation must be involved in this process. 
However, the source of this regulation is yet unclear. In the case of CesT-Tir in EPEC, it is 
proposed that temporal coexpression of effectors and chaperones may be the mechanism that 
confers Tir secretion priority as cesT and tir genes are cotranscribed and replacing tir gene with 
other effectors enhanced the secretion of those effectors (Thomas et al., 2007).  Nevertheless, it 
is unlikely to be a general mechanism since most class 1B chaperones are unlinked from its 
cargos in genome location. It is possible that these effectors may be present in different 
abundances or that the 3D secretion signal is different between each chaperon-effector 




Using isothermal titration calorimetry (ITC), Dr. Chul-Jin Lee found that Mcsc has the 
highest binding affinity to Ct618, then Ct225, and then Cap1 (Table 1). This order is reverse to 
the timing of gene transcription for these three Incs during Chlamydia infection and also our 
protein expression profile analysis (Bellend 2003) (Figure 3). We reasoned that this inverse 
correlation is a strategy that Chlamydial T3S system uses to ensure correctly ordered secretion 
of effectors. We proposed a model of a hierarchy secretion imparted by T3S Chaperone Mcsc 
during Chlamydia infection (Fig. 7). In the beginning of infection, because no other substrates 
are competing with Cap1, it binds to Mcsc and gets secreted right away. Later on when Ct225 is 
expressed, since some Cap1 is still inside Chlamydia, Ct225 will have to compete with Cap1 for 
limited number of Mcsc molecules. Similarly, when Ct618 is expressed, it now has to compete 
with both Cap1 and Ct225 for Mcsc. We hypothesized that a higher binding affinity for Mcsc 
allows the effector expressed later to compete with existing effector to be secreted by the 
system right after translation. This affinity-based regulation may be especially important for an 
obligate intracellular parasite like Chlamydia since different effectors are translated sequentially 
and secreted at various stages of infection to establish a suitable replicative niche inside host 
cells. Similar regulation may also be employed by other pathogenic Gram-negative bacteria since 
many T3S components are conserved (Buttner, 2012); an evolutionarily conserved mechanism 
may be shared.  
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3. Type III Secretion chaperones interact with multiple proteins 
in the Chlamydia elementary body 
3.1 Introduction 
3.1.1 Functions of Type III Secretion Chaperones 
Chlamydia trachomatis, like many Gram-negative bacteria pathogens, use a type III 
secretion (T3S) system to deliver effector proteins into its mammalian host cells. The secretion 
of many effectors often requires help of accessory proteins, called T3S chaperones. Depending 
on the type of their client protein cargos, T3S chaperones can be divided into three classes: class 
III chaperones prevent pre-oligomerization of needle components in the bacterial cytoplasm 
before secretion; class II chaperones stabilize translocators by binding their hydrophobic 
regions, and class I chaperones stabilize and/or enhance effector secretion (Cornelis, 2006). 
Besides these traditional roles, additional cellular functions have been uncovered for class II and 
class I chaperones. For instance, SicA, a Salmonella T3S chaperone for the effector SipA, directly 
interacts with the transcriptional activator InvF, and this complex activates the expression of T3S 
genes (Darwin & Miller, 2001). Similarly, SycD (LcrH), the chaperone for the translocator protein 
YopD, functions with YopD to represses T3S effector synthesis in Yersinia pseudotuberculosis 
(Francis, Lloyd, & Wolf-Watz, 2001).  In Chlamydia, the chaperone Scc4 (Ct663) negatively 
regulates σ66–dependent transcription by directly interacting with both σ66 and β subunits of 
RNA polymerase (Rao et al., 2009). At least one T3S chaperone, the Shigella Spa15 protein, is 
secreted and plays a role in preventing apoptosis of the infected host cell elicited by 
staurosporine (Faherty & Maurelli, 2009). Furthermore, as discussed in the previous chapter, 
class I chaperones have been suggested to play a role in determining the secretion hierarchy of 
their cognate effectors. 
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3.1.2 Chlamydia T3S Chaperones 
Based on their primary amino acid sequence, C. trachomatis encodes at least six 
putative T3S chaperones: Slc1(Ct043), Scc1(Ct088), Scc2(Ct576), Scc3(Ct862), Ct274 and 
Scc4(Ct663) (Fields KA, 2006; Stephens et al., 1998). Several studies have validated their 
function as chaperones and have identified the substrates they engage. For instance, Slc1 from 
C. trachomatis interacts with TARP and enhances its translocation/secretion in a heterologous 
Yersinia T3S system (Brinkworth et al., 2011; Pais et al., 2013). Scc1 and Scc4 from C. 
pneumoniae enhance the secretion of CopN, whereas Scc3 inhibits CopN secretion (Silva-Herzog 
et al., 2011). Scc2 is classified as a class II chaperone due to its interaction with CopB and CopD, 
translocator proteins in Chlamydia T3S system (Fields et al., 2005; Spaeth et al., 2009). 
Additional T3S chaperones have been defined functionally.  For example, Mcsc (Multiple Cargo 
Secretion Chaperone), which does not share any obvious sequence homology with known 
chaperones, was identified based on its ability to bind and stabilize the inclusion membrane 
proteins, Cap1 and Ct618 (Spaeth et al., 2009). Moreover, Mcsc shares extensive structural 
homology to class I chaperones as detailed in chapter 2. In addition, CdsE and CdsG, chaperones 
of the needle component CdsF, were identified based on their interactions with CdsF and 
requirements for CdsF stability when expressing in Escherichia coli (Betts et al., 2008). 
3.1.3 The EB is pre-packed with multiple T3S-related proteins  
A quantitative proteomic study indicated that the EB form of C. trachomatis is equipped 
with a complete set of T3S machinery and is pre-packed with an abundant arsenal of putative 
T3S effectors and chaperones (Saka et al., 2011). In addition to TARP, Ct694 and Ct695, over 50 
Chlamydia-specific hypothetical proteins lacking signal peptides (~7% of the molar mass of the 
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EB form) were also identified.  Since multiple effectors are likely translocated during invasion, a 
significant number of these Chlamydia-specific proteins may function as effectors with 
important roles early in infection. Interestingly, the EB form also contains a full complement of 
known T3S chaperones, with Slc1, Scc2 and Mcsc being the most abundant (Fig. 8A) (Saka et al., 
2011).  Given their abundance and that genes encoding these chaperones are topologically 
unlinked from genes for their effector protein cargos; we postulated that Slc1 and Mcsc may 
engage additional effectors in EBs. In addition, since the homologs of Scc2 in other bacteria have 
been shown to perturb gene transcription and Scc2 contains tetratricopeptide repeats (TPR), 
which are implicated in protein-protein interactions other than cargo-chaperone interactions, 
we hypothesized that Scc2 may interact with other EB proteins and play regulatory roles during 
Chlamydia infection. Hence, we aimed to map the interactome of Slc1, Scc2 and Mcsc, in EBs, to 
1) identify potential T3S effectors and 2) uncover additional roles these chaperones may play.  
 
In this study, we immunoprecipitated Slc1, Scc2 and Mcsc from Chlamydia EB lysates 
and identified co-purifying proteins by mass spectrometry.  We reported that Scc2 and Slc1 
represent central nodes of protein interaction networks. In contrast, only a limited number of 
interactions were associated with Mcsc in EBs.  Scc2 displayed the most extensive set of protein-
protein interactions, including the putative T3S translocator proteins, CopB and CopD, proteins 
with known roles in carbon metabolism, several ORFs of unknown function, and components of 
the RNA polymerase complex.  On the other hand, Slc1 co-precipitated with TARP, an effector 
essential for EB invasion (Jewett, Miller, Dooley, & Hackstadt, 2010), two known T3S effectors, 
Ct694 and Ct695, as well as several additional abundant Chlamydia-specific EB proteins, 
including a putative inclusion membrane protein, Ct365, and a hypothetical protein, Ct875. In 
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this chapter, we provide evidence that Slc1 formed stable complexes with these proteins in vitro 
and enhanced their secretion in a Yersinia T3S assay, establishing its role as a bona fide multi-
cargo T3S chaperone.  In the process, we also identified Ct875 as a potential T3S effector due to 
its capability to be secreted by the Yersinia T3S.  Immunodepletion of Slc1 from EB lysates led to 
a co-depletion of TARP and Ct694, indicating that these effectors in EBs are all present in T3S 
chaperone-containing complexes. We postulate that at the EB stage, a hierarchy in protein 
secretion is partially imparted by T3S chaperones and that by defining the chaperone-effector 
landscape in EBs we might be able to assign potential roles to effector protein during invasion, 
nascent inclusion generation and development of early-stage infection. 
3.2 Materials and Methods 
3.2.1 Cell lines, bacterial strains and reagents  
Chlamydia trachomatis biovar LGV, serotype L2, strain 434/Bu was propagated in HeLa 
cells or Vero cells maintained in Dulbecco's Modified Eagle Medium (Sigma-Aldrich, St. Louis, 
Missouri, USA) supplemented with 10% fetal bovine serum (FBS)(Mediatech, Manassas, Virginia, 
USA).  EBs were purified by density gradient centrifugation using Omnipaque 350 (GE 
Healthcare, Princeton, New Jersey, USA) as previously described (Saka et al., 2011). All 
recombinant protein expression was performed in Escherichia coli strain BL21(DE3). The Y. pestis 
KIM8-E (Δail) strain (Bartra et al., 2008) used in this study is avirulent and is excluded from the 
National Select Agent Registry due to the lack of the 102-kb pgm locus (Une & Brubaker, 1984). 
In addition, this strain carries deletions of the yopE, sycE and ail genes and has been cured of the 
plasminogen activator (Pla)-encoding pPCP1 plasmid. All experiments with Y. pestis KIM8-E (Δail) 
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were reviewed and approved by the Institutional Biosafety Committee at the University of 
Miami.  All reagents used are of analytical grade.  
3.2.2 Generation of antibodies and immunoblot analysis  
Antibody generation was performed as described in the previous chapter. Briefly, 
recombinant proteins: 10His-tagged Slc1 (Ct043), Mcsc (Ct260), and Scc2 (Ct576), and GST-
tagged Ct875 were purified on affinity resins and used to immunize New Zealand White rabbits. 
Anti-GST antibodies were removed by pre-incubation with GST-crosslinked resins, and anti-
Ct875 antibodies were affinity purified with Ct875 recombinant protein. Primary antibodies 
used in immunoblot analysis include anti-Tarp and Ct694 (1:1000) (generated in our laboratory), 
MOMP (1:2000) (gift from Dr. K. Fields), Ct875, Slc1, Mcsc and Scc2 (1:1000) (generated in this 
study), CdsD (1:1000) (gift from Dr. K. Fields), CopB (1:1000) (gift from Dr. T. Hackstadt) and 
RpoB/B’ and RpoD (1:1000) (gift from Dr. M. Tan, UC, Irvine). 
3.2.3 Identification of proteins that interact with T3S chaperones 
Immunoprecipitation (IP). Antibodies against Slc1 and Mcsc were crosslinked separately 
to protein A/G resins (Pierce, Rockford, Illinois, USA) using 40 mM Dimethyl pimelimidate 
(Sigma-Aldrich, St. Louis, Missouri, USA) and the reactions were quenched with 40 mM 
ethanolamine (Sigma-Aldrich, St. Louis, Missouri, USA). Pre-immune serum was also crosslinked 
to resins and served as a negative control. Approximately 3x1010 EBs were lyzed by sonication in 
1 mL Pierce IP lysis buffer (25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 % NP-40, 5 % glycerol; pH 
7.4)(Pierce, Rockford, Illinois, USA) supplemented with 1 mM phenylmethylsulphonyl fluoride 
(PMSF) and 1X EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland). After 
centrifugation to pellet down insoluble debris, the lysate was incubated with the antibody-
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crosslinked resins at 4°C for 4 hours. After 3 washes with IP lysis buffer, the bound proteins were 
eluted with Pierce Elution buffer (pH 2.8)(Pierce, Rockford, Illinois, USA) and separated via SDS-
PAGE on a 4-12 % Bis/Tris gradient gel (Invitrogen, Life Technologies, Carlsbad, CA, USA).  Lanes 
were sliced into 8-10 equivalent sections for in-gel digestion and analyzed by mass spectrometry 
at the Duke Proteomics Core facility. 
 
Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry (LC-MS/MS). 
The in-gel digested peptides from each band were analyzed via LC-MS/MS as follows:  
Approximately ½ of each digest (5 µL) was first trapped for 5 min on a 5 µm Symmetry C18 180 
µm I.D. X 20 mm column at 20 µl/min in 99.9 % mobile phase A, then an analytical separation 
was performed using a 75 µm x 250 mm BEH C18 column (Waters Corp., Milford, Maryland, 
USA) with a gradient of 5 to 40 % mobile phase B over 30 minutes, with a flow rate of 0.4 µL/min 
at 55°C column temperature, using a nanoAcquity liquid chromatograph (Waters Corp., Milford, 
Maryland, USA).  The mobile phase consisted of (A) 0.1 % formic acid in water and (B) 0.1 % 
formic acid in acetonitrile.  Electrospray ionization was used to introduce the sample in real-time 
to a Synapt G2 Q-Tof mass spectrometer (Waters Corp., Milford, Maryland, USA), collecting data 
for each sample in data-dependent analysis mode with 0.6 second survey scans and three 0.6-
second MS/MS scans in CID mode of the top three most abundant multiply-charged precursor 
ions.  Raw data was processed in Mascot Distiller (v2.3) and searched in Mascot v2.2 (Matrix 
Science) against a concatenated database containing the deduplicated entries from NCBInr with 
Chlamydia trachomatis taxonomy (http://www.ncbi.nlm.nih.gov/pubmed/).  For QToF data, 
search tolerances in Mascot were 10 ppm on precursor and 0.04 Da on product ions, requiring 
full trypsin specificity and allowing at most 2 missed cleavages.  Carbamidomethylation 
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(+57.0214 Da, Cys) was included as a fixed modification, and deamidation (Asn and Gln) and 
oxidation ((+15.9949 Da, Met) were allowed as variable modifications.  Scaffold (v3.6.2, 
Proteome Software Inc.) was used to validate MS/MS based peptide and protein identifications. 
Peptide identifications were accepted if they could be established at greater than 80% 
probability as specified by the Peptide Prophet algorithm, and protein identifications were 
accepted if they could be established at greater than 90% Protein Prophet probability and 
contained at least 2 identified peptides (Keller, Nesvizhskii, Kolker, & Aebersold, 2002; 
Nesvizhskii, Keller, Kolker, & Aebersold, 2003). The overall peptide and protein false discovery 
rate is 0 %. Results were from three independent biological replicates for Slc1 and Mcsc and two 
independent biological replicates for Scc2.  
3.2.4 Co-purification of Slc1 with GST-tagged effectors and Gel Filtration (Size 
exclusion chromatography)  
E. coli BL21(DE3) was co-transformed with a pET24d vector expressing Slc1 and pGEX 
vector alone or pGEX expressing individual GST-tagged test protein. Protein expression was 
induced using 0.5 mM isopropyl-1-thio-β-d-galactopyranoside (IPTG) for 3 hours at 37°C. Cells 
were pelleted and lysed by sonication in binding buffer (1 % Triton X-100, 20 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 1 mM PMSF, pH 7.4), and GST–tagged proteins were isolated from the 
supernatant using glutathione-Sepharose beads (GE Healthcare, Pittsburgh, PA, USA). After 4 h 
incubation, beads were washed 3 times with binding buffer, followed by 3 washes with washing 
buffer (0.2 % Triton X-100, 300 mM NaCl).  Bound proteins were solubilized in 1X Laemmli 
sample buffer (20 mM Tris-HCl, pH 6.8, 1% SDS, 5% Glycerol, 10 mM DTT, 0.01% bromophenol 
blue) and resolved by SDS PAGE, followed by immunoblot analysis with anti-Slc1 and –GST 
antibodies. Gel filtration chromatography was performed on proteins expressed in E. coli using a 
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bi-cistronic vector to co-express untagged Slc1, with His-tagged test proteins. The protein 
complexes were first purified using a Nickel resin (GE Healthcare, Pittsburgh, PA, USA), eluted 
with 500 mM imidazole and applied to a Superdex 200 gel filtration column (GE Healthcare, 
Pittsburgh, PA, USA) for analysis. Fractions from each sample were collected and analyzed by 
immunoblot with anti-His and anti-Slc1 antibodies.  Size markers, alcohol dehydrogenase (150 
kDa), Conalbumin (75 kDa) and Carbonic Anhydrase (29 kDa) were purchased from GE (GE 
Healthcare, Pittsburgh, PA, USA) and Sigma (Sigma-Aldrich, St. Louis, Missouri, USA). 
3.2.5 Yersinia pestis T3S assays 
Yersinia pestis KIM8-E (Δail) was co-transformed with the compatible plasmids pBAD33 
and pBAD24 (Appendix 1) either alone or in combination with pBAD plasmids encoding T3S 
chaperones and putative effectors. Transformed bacteria were grown overnight at 27°C in TMH 
media supplemented with ampicillin and chloramphenicol. Overnight cultures were used to 
inoculate fresh TMH media containing 2.5 mM calcium or without calcium at OD620 = 0.2 and 
incubated for 1 hour at 27°C. L-arabinose was added to 0.2 % final concentration to induce 
chaperone and effector proteins expression and the culture temperature was shifted to 37°C for 
5 hours. Bacteria were harvested by centrifugation and cell pellets were separated from culture 
supernatants. Proteins in the supernatant fractions were precipitated with 10 % (v/v) 
trichloroacetic acid, resuspended in 1X SDS-PAGE sample buffer and normalized to the final 
OD620 of the respective culture. 
 40 
3.3 Results 
3.3.1 The type III secretion chaperones Slc1 and Scc2 associate with multiple C. 
trachomatis proteins. 
A quantitative proteomics analysis of C. trachomatis indicated that around 2% of the EB 
total mass is composed of T3S chaperones, with Slc1, Mcsc and Scc2 accounting for over 99% of 
all known T3S chaperones (Fig. 8A) (Saka et al., 2011).  Slc1 forms complexes with TARP and 
enhances TARP translocation into HeLa cells when both proteins are co-expressed in Yersinia 
enterocolitica (Brinkworth et al., 2011; Pais et al., 2013).  In EBs, the majority of TARP is in 
complex with Slc1, and both TARP and Slc1 are present at similar molar concentrations (Saka et 
al., 2011).  However, since slc1 is located ~500 kb from tarP, it is unlikely that Slc1 constitutes a 
TARP-specific Class IA T3S chaperone.  Furthermore, because putative T3S effectors in EBs are 
present at a 10 fold molar excess over the three major T3S chaperones (Saka et al., 2011), we 
hypothesized that chaperones like Slc1 and Mcsc must bind multiple effectors.  To test this 
premise we determined the compendium of EB proteins that associate with Slc1 and Mcsc.  We 
immunoprecipitated (IP) Slc1 and Mcsc under native conditions from EB lysates and identified all 
proteins that associated with each individual chaperone by LC-MS/MS (liquid chromatography-
tandem mass spectrometry).  As previously reported (Brinkworth et al., 2011; Saka et al., 2011) 
TARP was one of the major proteins that co-purified with Slc1.  In addition, two predicted T3S 
effectors, Ct694 and Ct695, and two hypothetical proteins, Ct365 and Ct875 co-purified with 
Slc1 (Fig. 8B).  CdsD, a T3S apparatus component, and proteins involved in metabolism were also 
specifically detected in the Slc1 IP samples (Table 2). Interestingly, both Mcsc and Slc1 mutually 
co-immunoprecipitated each other.  Since these chaperones are not predicted to form 
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heterodimers (Brinkworth et al., 2011), this result suggests that Slc1 and Mcsc homodimers may 
co-chaperone the same cargo, presumably Ct365, which was detected in both IP samples.   
 
The same analysis was also performed on a class II T3S chaperone abundant in EBs, Scc2. 
Scc2 constituted another central hub of the T3S chaperone interactome in EBs. In addition to 
the known interactors CopB and CopD, the putative T3S translocator proteins in Chlamydia 
(Fields et al., 2005; Spaeth et al., 2009), several membrane-associated proteins were also 
detected (Fig 8B).  Since a portion of Scc2 associates with Chlamydia membranes as shown by 
biochemical fractionation (Fields, Mead, Dooley, & Hackstadt, 2003), interactions with 
membrane proteins may keep Scc2 in close proximity to membranes. In addition, Scc2 co-
precipitated with proteins with known roles in carbon metabolism, several ORFs of unknown 
function, and components of the RNA polymerase complex (Fig. 8B)(Table 2), implying a 
potential coupling between T3S activation and metabolic switches and gene transcription during 






Figure 8: A distinct set of Chlamydia proteins associate with Slc1 and Scc2 in the Elementary 
Body (EB) form. A) Relative protein mass composition of the C. trachomatis EB.  Approximately 
2 % of total EB protein mass is comprised of T3S chaperones, with Slc1, Scc2 and Mcsc 
accounting for over 99 % of their mass.  This figure represents a reanalysis of data reported in 
(Saka et al., 2011). B) Protein interaction network for Slc1, Scc2 and Mcsc.  Cell lysates from 
gradient purified EBs were incubated with anti-Slc1 antibodies, anti-Scc2 antibodies anti-Mcsc 
antibodies, or non-specific IgG cross-linked to protein A/G resins. Bound proteins were eluted at 
low pH, digested with trypsin and identified by liquid chromatography coupled to tandem mass 




Table 2: Number of unique spectruma identified by LC-MS/MS from samples immunoprecipitated with anti-Slc1, anti-Scc2 and anti-
Mcsc antibodies from Chlamydia EBs*. 
      
  
Control Mcsc Slc1 Scc2 





























1 T3S chaperone gi|237804605 19 Mcsc (Ct260) 0 0 0 0 7 12 12 0 2 5 0 2 
2 T3S chaperone gi|237804393 18 Slc1 (Ct043) 0 0 0 1 1 1 4 7 22 31 0 1 
3 T3S chaperone gi|165931654 26 Scc2 (Ct576) 0 0 0 1 0 0 0 0 0 0 14 21 
4 
Putative integral membrane 
protein gi|165931439 61 Ct365 0 0 0 0 0 0 8 2 2 11 0 0 
5 T3S effector gi|165930024 35 Ct694 0 0 0 0 0 0 1 6 16 23 0 0 
6 T3S effector gi|165930025 44 Ct695 0 0 0 0 0 0 0 1 8 25 0 0 
7 
Translocated actin-recruiting 
phosphoprotein gi|48869193 103 Tarp (Ct456) 0 0 0 0 0 0 0 9 15 34 0 0 
8 
Translocated early 
phosphoprotein gi|165930209 66 TepP (Ct875) 0 0 1 0 0 0 0 5 7 24 2 2 
9 
60-kDa cysteine-rich outer 
membrane protein precursor gi|144487 56 OmcB (Ct443) 0 0 1 0 0 0 1 0 1 0 10 8 
10 
DNA-directed RNA polymerase 
alpha chain gi|165931585 42 RpoA (Ct507) 0 0 2 3 0 0 3 0 1 0 10 6 
11 
DNA-directed RNA polymerase 
beta chain gi|51538993 140 RpoB (Ct315) 0 0 0 0 0 0 0 0 0 0 20 4 
12 
DNA-directed RNA polymerase 
beta-prime chain gi|165930512 155 RpoC (Ct314) 0 0 0 0 0 0 0 0 0 0 33 9 
13 T3S translocon gi|15605307 50 CopB (Ct578) 0 0 0 0 0 0 0 0 0 0 0 10 
14 T3S translocon gi|165931657 44 CopD (Ct579) 0 0 0 0 0 0 1 0 0 0 3 14 
15 
Phosphopeptide binding 
protein (TTS component) gi|165929994 90 CdsD (Ct664) 0 0 0 0 0 0 0 0 12 13 0 0 
16 Chaperone protein gi|237804743 71 DnaK (Ct396) 0 0 0 0 0 0 0 0 3 10 10 4 
17 Serine protease gi|165931030 53 HtrA (Ct823) 0 0 1 2 0 0 1 0 4 4 8 3 






of pyruvate dehydrogenase 
complex gi|165931321 46 Ct247 0 0 0 0 0 0 0 0 1 0 6 6 
20 Transaldolase  gi|165931386 36 Ct313 0 0 0 1 0 0 0 3 13 20 2 2 
21 Fructose-bisphosphate aldolase gi|165931288 38 Ct215 0 0 0 1 0 0 3 0 0 0 3 5 
22 30S ribosomal protein S9 gi|255310927 15 Ct126 0 0 0 0 0 0 0 0 0 0 5 3 
23 SSU ribosomal protein S13P gi|237804860 14 Ct509 0 0 1 2 0 0 0 0 0 0 4 6 
24 
Late transcription unit B 
protein gi|237804429 11 Ct080 0 0 0 0 0 0 0 0 1 7 0 0 
25 
Polymorphic membrane 
protein H gi|148728350 105 PmpH (Ct872) 0 0 0 0 0 0 0 0 0 0 2 2 
26 
Polymorphic outer membrane 
protein G gi|165931080 107 PmpG (Ct871) 0 0 0 0 0 0 0 1 0 2 4 2 
27 
Low calcium response protein 
D gi|237802522 78 Ct090 0 0 0 1 0 0 0 0 1 1 3 1 
28 
Single-stranded-DNA-specific 
exonuclease gi|165931524 65 RecJ (Ct447) 0 0 0 0 0 0 0 0 0 0 3 5 
29 
Inner membrane protein 
(membrane protein insertase) gi|165931325 88 YidC (Ct251) 0 0 0 0 0 0 0 0 0 0 3 3 
30 
3-oxoacyl-[acyl-carrier-protein] 
synthase gi|165930975 45 FabF (Ct770) 0 0 0 0 0 0 0 0 0 1 2 3 
31 Hypothetical protein gi|14195440 39 Ct429 0 0 0 0 0 0 0 0 0 0 2 3 
32 ATP-dependent protease La  gi|165931419  92 Ct344 0 0 0 0 0 0 0 0 0 0 4 1 
       *Results shown are from three independent experiments of IP, followed by mass spectrometry analysis using control IgG   antibodies and antibodies against Mcsc, Slc1 or Scc2. 
       *Proteins identified with less than 3 unique spectra or found to be less than 2 fold more abundant than in control IgG samples were not included. Exp -experiment 
         aUnique spectrum: Two spectra are unique if they match different peptides (even if the peptides overlap), or if they match two different charge states of the same peptide, or different modified      
        forms of the same peptide.  
         bAccession number for NCBI  
         cGene name or CT nomenclature based on C. trachomatis serovar D 
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3.3.2 Validation of proteomics result by immunoblots 
We validated the LC-MS/MS results by immunoblot analysis of the IP materials and 
immunodepleted flow-through samples with antibodies specific to Slc1, Scc2 and the identified 
co-precipitating proteins (Fig. 9).  We detected TARP, Ct694, Mcsc, CdsD and Ct875 in samples 
immunoprecipitated with anti-Slc1 antisera but not with pre-immune antisera.  In contrast, 
MOMP, a very abundant EB protein, was not detected in the Slc1 IP samples, highlighting the 
specificity of the immunoisolations. In addition, Scc2, RpoB/B’, RpoD, and CopB were detected 
in samples immunoprecipitated with anti-Scc2 antisera but not with pre-immune antisera (Fig. 
9).  As we had previously observed, immunodepletion of Slc1 from EB lysates led to a co-
depletion of TARP (Saka et al., 2011).  Similarly, Ct694 was also substantially depleted, indicating 
that these two effectors within EBs are largely present in Sc1-containing complexes.   The other 
co-purifying targets were not efficiently co-depleted which suggest that the complexes were 




Figure 9: Specificity of Slc1 and Scc2 interactions. EB lysates were incubated with anti-Slc1 
antisera, anti-Scc2 antisera or pre-immune sera, and bound proteins were captured on Protein 
A/G resins.   The eluate (bound) and flow through (unbound) from Slc1 IP, Scc2 IP and control IP 
were analyzed by immunoblot with antibodies against selected proteins. MOMP (major outer 
membrane protein) is an abundant Chlamydia protein that serves as control for the specificity of 
the interactions shown. 
 
3.3.3 Slc1 forms stable complexes with the effectors TARP, Ct694, Ct695 and 
Ct875. 
We next tested if the major interactions identified for Slc1, especially those with 
potential T3S effectors, could be recapitulated in vitro with recombinant proteins.   The most 
abundant proteins that associated with Slc1 are Ct875, TARP, Ct694, Ct695 and Ct365.   We 
expressed these proteins as GST-tagged fusion proteins together with untagged Slc1 in E. coli 
and tested whether Slc1 would co-purify on glutathione sepharose beads.  Because, we could 
not express the predicted inclusion membrane protein Ct365 (Toh et al., 2003) in E. coli, this 
potential effector was not studied further (data not shown).  Pull downs of GST-tagged TARP, 
Ct694, Ct695 and Ct875 with glutathione beads led to the co-isolation of Slc1.  This binding was 
specific as neither GST nor GST-tagged Ct288, another inclusion membrane protein (Li et al., 
2008) that is present in EBs, led to Slc1 co-purification (Fig. 10A).  T3S chaperones form stable 
complexes with a predicted 2:1 stoichiometry of chaperone to effector protein (Feldman & 
Cornelis, 2003).  To test if such larger complexes could form, we co-expressed in E. coli untagged 
Slc1 and hexahistidine-tagged full length TARP, Ct694, Ct695, or Ct875 and isolated protein 
complexes on nickel resins.  The bound material was eluted from the resin with imidazole and 
analyzed by gel filtration chromatography.  All four proteins formed stable complexes with Slc1, 
with apparent molecular weights above 150 kDa, which are larger than that expected for 2:1 
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chaperone effector complexes (Fig. 10B).  Although gel filtration cannot always accurately 
predict molecular sizes for non globular proteins (Erickson, 2009), given that TARP forms 
hexamers and that the oligomerization domain is distinct from the Slc1 binding domain 
(Brinkworth et al., 2011; Jewett et al., 2010), we postulate that size discrepancies between 
Slc1/Tarp and the other Slc1/effector complexes represent the formation of higher order 
oligomeric forms. 
 
Figure 10: Slc1 associates as stable, multi-protein complexes with TARP, Ct694, Ct695 and 
Ct875. A-B) Slc1 binds its putative target effectors in vitro. Slc1 was co-expressed in E. coli with 
GST-tagged TARP, Ct694, Ct695 and Ct875 fusion proteins. The GST-tagged proteins were 
isolated from cell lysates with glutathione sepharose beads, and the relative levels of Slc1 co-
isolated was assessed by immunoblot analysis (A). GST and GST-288 served as negative controls. 
To assess the relative size of these complexes, TARP, Ct694, Ct695 and Ct875 were fused to a 
hexahistidine tag and co-expressed with Slc1.  Bound proteins were purified using a Nickel resin, 
eluted with 500 mM Imidazole, and analyzed by gel filtration chromatography (B).  Fraction 
numbers are provided on the top. Molecular size markers: Alcohol Dehydrogenase (150 kDa), 
Conalbumin (75 kDa) and Carbonic Anhydrase (29 kDa), peaked at F16-17, F20-21 and F26, 
respectively. No peak was observed between fractions 8-20 in Slc1-6xHis samples in the absence 
of co-expressed effectors. 
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3.3.4 Slc1 enhances the secretion of Ct694, Ct695 and Ct875 in a heterologous 
T3S system 
Based on the gel filtration results we speculated that Slc1, as reported for TARP 
(Brinkworth et al., 2011), would act as T3S chaperone and enhance the secretion of Ct694, 
Ct695, and Ct875.  To test this premise, we reconstituted chaperone-assisted T3S in Y. pestis as 
previously described (Silva-Herzog et al., 2011).  Effectors were expressed in Y. pestis as either 
untagged (Ct694 and Ct875) or FLAG-tagged (Ct695) proteins under the control of an arabinose-
inducible promoter in the presence of Slc1 or Mcsc.  Upon induction of T3S by calcium chelation, 
Ct694 and Ct695 were secreted into the supernatants as previously reported (Hower, Wolf, & 
Fields, 2009).  The secretion of Ct694 and Ct695 was enhanced two to three fold when Slc1, but 
not Mcsc, was co-expressed, suggesting that Slc1 functions as a bona fide T3S chaperone specific 
for these proteins (Fig. 11).   Consistent with the known behavior of most T3S chaperones, 
neither Slc1 nor Mcsc were secreted into supernatants (data not shown). The role of Slc1 in 
TARP secretion in this system could not be determined as expression of full length TARP in the 
presence of Slc1 hindered Y. pestis T3S (data not shown).  Interestingly, full length Ct875 was 
also a target of secretion by the Y. pestis T3S system, even though Ct875 is not predicted to have 
a T3S signal (Arnold et al., 2009; Saka et al., 2011; Samudrala, Heffron, & McDermott, 2009), and 
its secretion was enhanced by Slc1. This suggested that Ct875 is a potential T3S effector in 
Chlamydia and Slc1 is its chaperone. 
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Figure 11: Slc1 enhances the T3S-dependent secretion of Ct694, Ct695 and Ct875. Y. pestis 
KIM8-E (Δail) was co-transformed with plasmids expressing Ct694, Ct875/TepP and FLAG-tagged 
Ct695 and untagged Slc1 or Mcsc in the combinations shown. T3S was induced by calcium 
chelation and the relative amount of protein secreted into the supernatants was assessed by 
quantitative immunoblots.  Sup-cell free supernatant.  Mcsc did not enhance the secretion of 




Immunoprecipitation followed by proteomics analysis has given us new insights into the 
interactome of T3S chaperones in C. trachomatis EB.  The two most abundant class I T3S 
chaperones in EBs are the TARP chaperone Slc1 (Brinkworth et al., 2011; Saka et al., 2011) and 
Mcsc, which engages at least two inclusion membrane proteins during the RB stage (Spaeth et 
al., 2009).  Because the genes encoding Slc1 and Mcsc are unlinked from that of their effectors, 
we considered the possibility that these chaperones engage multiple effectors in EBs. To test 
this premise we decided to identify the set of proteins that stably associate with Slc1 and Mcsc 
at the EB stage by IP coupled to mass spectrometry. We only found a limited number of 
interactions for Mcsc in EBs, suggesting that Mcsc may function mainly post entry.  In contrast, 
Slc1 engaged at least four new substrates of the T3S system: Ct365, Ct694, Ct695 and Ct875, a 
protein not previously thought to harbor a T3S signal based on early prediction algorithms 
(Arnold et al., 2009; Samudrala et al., 2009).  We provide evidence that these proteins are T3S 
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cargos and that Slc1 is a bona fide multi-cargo T3S chaperone. Consistent with our findings, 
Mota’s group recently showed that Slc1 can interact with Ct694 and Ct695 in vitro and enhances 
their secretion in Y. enterocolitica (Pais et al., 2013).  
 
Although one class 1B T3S chaperone in Shigella is secreted during infection (Faherty & 
Maurelli, 2009), Slc1 itself is unlikely to be a T3S cargo as it was not secreted by Yersinia under 
inducing conditions (data not shown). Nevertheless, we identified several additional proteins 
that specifically co-IP with Slc1, including the late transcription unit B protein (ltuB, Ct080), a 
serine protease (HtrA), a putative aminopeptidase (PepA) and a transaldolase (TalB).   While not 
experimentally confirmed, it is unlikely that any of these proteins constitute T3S effectors as 
computational programs aimed at identifying T3S signals give these proteins very low 
confidence for T3S (www.effectors.org).   Similarly, Scc2, a class II T3S chaperone, pulled down 
many proteins involved in carbon metabolism and transcription machinery. Since homologs of 
Scc2 in Yersinia (SycD), Salmonella (SicA) and Shigella (IpgC) contribute to repression (SycD) or 
activation (SicA & IpgC) of T3S gene expression (Parsot et al., 2003), the associations with 
components of RNA polymerase complex suggest that Scc2 may play a regulatory role similar to 
these homologs and modulate T3S gene expression in Chlamydia. At present, it is unclear 
whether these interactions are direct.  However, one could envision scenarios wherein 
chaperones like Slc1 and Scc2 could interact with non-effector proteins to signal the successful 
entry into a host cell after it is no longer physical bound to an effector. Such a mechanism might 
be especially important for an intracellular pathogen like Chlamydia, where physical 
engagement of the T3S apparatus may need to be coupled to rapid metabolic adaptations, gene 
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transcription and post-translational modifications that drive successful colonization of the target 
cell.  
 
T3S chaperones enhance the secretion of its bound cargos by stabilizing them in the 
bacterial cytosol or maintaining them in a secretion competent state (Parsot et al., 2003).  In 
addition, T3S chaperones can also prioritize the secretion of cognate effectors as exemplified by 
YopE, a Yersinia T3S effector, whose secretion is severely impaired in the presence of other 
effectors when lacking a SycE chaperone binding site, indicating that additional secretion signals 
are either unmasked or conferred by the T3S chaperone (Boyd et al., 2000).  Similarly, a real-
time analysis of CesT-dependent traslocation revealed a distinct order in the translocation of 
enteropathogenic Escherichia coli effectors and the effector-chaperone interaction is 
suggested to be one of the determining factors of translocation efficiency (Mills et al., 2008). 
Based on these findings, we hypothesized that T3S chaperones would play a prominent role in 
establishing a hierarchy to the secretion of effectors by Chlamydia EBs.  The most abundant T3S 
chaperone in EBs is Slc1, which, like CesT, engages multiple effectors. TARP, one of Slc1s’ 
cargoes (Brinkworth et al., 2011), is secreted within 5 min upon EB attachment to epithelial cells 
(Clifton et al., 2004). Interestingly, the majority of TARP in EBs is found pre-complexed with Slc1 
(Fig. 9) (Saka et al., 2011), implying that this pre-engagement with its chaperone could prime 
TARP for rapid secretion.  Similarly, a significant proportion of Ct694 within EBs is pre-
complexed with Slc1 (Fig. 9), suggesting that Ct694 may be also secreted very early during 
infection, possibly at the same time as TARP.   In contrast, only a minor portion of Ct875 was 
present in complexes with Slc1 in EBs, even though Ct875 is more abundant than TARP and 
Ct694 (Saka et al., 2011).  Given these observations, we considered a model wherein T3S 
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substrates pre-bound by Slc1 in EBs, such as TARP and Ct694, will be delivered first, followed by 
Ct875 and potentially others effectors which do not exist as pre-formed chaperone complexes in 
EBs.
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4. Identification of TepP as a new tyrosine-phosphorylated T3S 
effector that mediates a host scaffolding protein recruitment to 
nascent inclusions and host innate immune signaling 
4.1 Introduction 
4.1.1 T3S effectors in Chlamydia 
Like many Gram-negative bacterial pathogens, Chlamydia uses a type III secretion (T3S) 
system to deliver effector proteins into their target host cells (reviewed in (Peters et al., 2007)). 
These effectors interfere with diverse host cellular processes including signaling, cytoskeletal 
rearrangements, and vesicle trafficking to enhance bacterial entry, establish a replicative niche 
and evade innate immunity (Betts et al., 2009).  At early stage of infection, the Translocated 
Actin Recruiting Protein (TARP) is delivered into the host cytoplasm after bacterial attachment 
(Clifton et al., 2004).  TARP facilitates invasion by mediating actin re-arrangements through the 
direct nucleation of F-actin polymerization and the recruitment of Rac-specific guanine 
nucleotide exchange factors (Jewett et al., 2010; Lane, Mutchler, Al Khodor, Grieshaber, & 
Carabeo, 2008).  Another T3S effector, Ct694, is delivered into host cells during Chlamydia entry 
where it engages the cytoskeletal organizing protein AHNAK (Hower et al., 2009). After entry, a 
new set of T3S effectors are synthesized and translocated to the inclusion membrane (Inc 
proteins) (Rockey, Scidmore, Bannantine, & Brown, 2002) where they mediate the recruitment 
of host proteins such as SNAREs, 14-3-3β, Rab proteins, signaling molecules and lipid 
transporters (Delevoye et al., 2008; Derre et al., 2011; Rzomp et al., 2006; Scidmore & 
Hackstadt, 2001). At later stages of infection, Chlamydia protein associating with death domains 
(CADD), is translocated into the host cell cytoplasm and interacts with death domains of tumor 
necrosis factor (TNF) family receptors and potentially induces apoptosis of infected cells 
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(Stenner-Liewen et al., 2002). In addition, Ct847, a mid-cycle gene product, interacts with host 
Grap2 cyclin D-interacting protein (GCIP), a multifunctional protein involved in cell cycle which is 
degraded in a proteasome-dependent pathway during Chlamydia infection (Chellas-Gery, 
Linton, & Fields, 2007).  Depletion of GCIP by siRNA prior to infection confers a growth 
advantage to C. trachomatis L2; nevertheless, whether Ct847 directly mediates GCIP 
degradation is still unclear. 
   
Although T3S effectors share a signal sequence at their N-terminus, these signals are 
relatively unstructured and poorly conserved, rendering computational prediction difficult.  
Although two algorithms are now available to predict T3S substrate, the prediction power is 
limited and has a high error rate (Mueller et al., 2013). Because until recently Chlamydia could 
not be readily manipulated with molecular genetic tools, most approaches to identify effectors 
have been indirect and relied on heterologous expression systems (Valdivia, 2008). In this 
manner, it is predicted that approximately 5-8 % of the C. trachomatis genome, or 45-70 genes, 
encode proteins for T3S.  However, few effectors have been confirmed as secreted and even 
fewer have described functions. This is especially true for the early stage of infection, in which 
only two effectors, TARP and Ct694, have been experimentally validated in C. trachomatis to 
date (Clifton et al., 2004; Hower et al., 2009).  Given the complexity of this early stage of 
infection, which comprises invasion and establishment of the early replicative niche, more 
effectors are expected to be involved in this process and await discovery.  
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4.1.2 Bacterial effector proteins are subjected to tyrosine-phosphorylation 
upon translocation into their target host cells  
Through co-evolution with their hosts, pathogens have evolved many mechanisms to 
hijack host cellular processes. One common strategy is to commandeer host signaling pathways 
through routes such as relocating host signaling molecules and inducing post-translational 
modifications (PTM) of host proteins or effectors themselves (Ribet & Cossart, 2010). An 
emerging field of bacteria-associated PTM is tyrosine phosphorylation as exemplified by Tir and 
CagA in Enteropathogenic Escherichia coli (EPEC) and Helicobactor pylori, respectively (Backert & 
Selbach, 2005). Tir (translocated intimin receptor) is secreted by the EPEC T3S system and 
inserts itself into the host plasma membrane.  After binding to the bacterial outer membrane 
protein, intimin, Tir is phosphorylated at tyrosine residue by multiple host kinases, triggering 
actin nucleation and pedestal formation beneath adherent bacteria (Kenny, 1999). On the other 
hand, CagA from H. pylori is tyrosine-phosphorylated upon translocation to host cells by T4S and 
this phosphorylation induces global cytoskeletal rearrangements, leading to cell scattering and 
elongation (Backert, Moese, Selbach, Brinkmann, & Meyer, 2001; Moese et al., 2004). In the 
case of C. trachomatis, TARP is tyrosine-phosphorylated after translocation and this 
phosphorylation is important for interactions with guanine nucleotide exchange factors, Sos1 
and Vav2, and subsequent actin remodeling (Lane et al., 2008). Additionally, phosphorylated 
TARP interacts with SHC1, a host adaptor protein that regulates apoptosis and growth-related 
genes (Mehlitz et al., 2010). SHC1 is phosphorylated and activated during Chlamydia infection in 
a phospho-TARP-dependent manner and SHC1 knockdown sensitized infected host cell to 
apoptosis, suggesting SHC1 activation stimulates survival signals to host cells. Significantly, 
phosphotyrosine immunoblot of cells early after Chlamydia infection indicates that multiples 
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proteins besides TARP are tyrosine-phosphorylated (Birkelund, Johnsen, & Christiansen, 1994; 
Fawaz, van Ooij, Homola, Mutka, & Engel, 1997). Two studies reported that host proteins, 
cortactin and ezrin, contribute to the observed signals (Fawaz et al., 1997; Swanson, Crane, & 
Caldwell, 2007). Nevertheless, since the molecular weights of these proteins only partially 
overlap the observed signals, additional unidentified proteins must exist. 
 
In chapter 3, we immunoprecipited Slc1 from Chlamydia EB lysates and identified co-
purifying proteins by mass spectrometry.  In this manner, we determined that Slc1 is in complex 
with multiple T3S effectors and that co-expression of Slc1 enhanced the secretion of these 
effectors in Yersinia pestis.  In this chapter, we describe how, based on this information, we 
identified and characterized a new effector, TepP (Translocated early phosphoprotein – Ct875), 
which is tyrosine-phosphorylated upon translocation into host cells. Given that TepP 
phosphorylation at Tyr residues occurs later with respect to TARP phosphorylation, we postulate 
that TARP may be secreted before TepP.  We further show that phosphorylated TepP associates 
with host scaffolding proteins Crk-I and Crk-II and that the recruitment of Crk proteins to 
nascent inclusions is absent in cells infected with a Chlamydia mutant harboring a tepP null 
allele and is restored in complemented strain. In addition, endocervical epithelial cells infected 
with this mutant exhibited transcriptional changes in a subset of innate immunity-related genes 
and different cell morphology compared to cells infected with complemented strain. We 
propose a model wherein TepP acts downstream of TARP to recruit scaffolding proteins that 
initiate and amplify signaling cascades important for establishing a replicative niche for 
Chlamydia within the infected host. 
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4.2 Materials and Methods 
4.2.1 Cell lines, bacterial strains and reagents  
Chlamydia trachomatis biovar LGV, serotype L2, strain 434/Bu was propagated in HeLa 
cells or Vero cells maintained in Dulbecco's Modified Eagle Medium (Sigma-Aldrich, St. Louis, 
Missouri, USA) supplemented with 10% fetal bovine serum (FBS) (Mediatech, Manassas, 
Virginia, USA). Human endocervical epithelial A2EN cells (Buckner et al., 2011) were maintained 
in keratinocyte-SFM medium (Gibco, Life Technologies corp., Grand Island, NY, USA) 
supplemented with 10 % FBS, 0.5 ng/mL human recombinant epidermal growth factor and 
50 μg/mL bovine pituitary extract.  EBs were purified by density gradient centrifugation using 
Omnipaque 350 (GE Healthcare, Princeton, New Jersey, USA) as previously described (Saka et 
al., 2011). All recombinant protein expression was performed in Escherichia coli strain 
BL21(DE3). 
4.2.2 Indirect immunofluorescence staining  
Approximately 5x104 HeLa cells/well were seeded onto glass coverslips placed in a 24 
well plate. The following day, cells were incubated with LGV-L2 EBs at an MOI of 20 and 
infections were synchronized by centrifugation (3000 rpm for 30 min) at 10°C followed by 
transferring the plates to a 37°C, 5 % CO2 humidified incubator.  At the indicated time points, 
the coverslips were fixed either with 100% methanol on ice for 15 min or with 3% 
formaldehyde/0.025% glutaraldehyde at room temperature for 20 min. Cells were then 
permeabilized with 0.2 % Triton in phosphate buffer saline solution (PBS), blocked with 3 % BSA 
in PBS for 30 min and stained with antibodies against TepP (1:10), mouse LPS (1:250)(EV1-H1), 
rabbit MOMP (1:250)(gift from K. A. fields), phosphotyrosine (1:100) (Cell signaling #9411), Slc1 
 58 
(1:100), Crk (1:10)(BD Transduction Laboratories 610035 clone 22). DAPI (Invitrogen Life 
Technologies, Carlsbad, CA, USA) was used for staining nucleic acids.  To permeabilize EBs at 
very early time points, 0.005% SDS in PBS was used. The images were further deconvolved using 
Huygens software (Scientific Volume Imaging, Hilversum, Netherlands).  
4.2.3 Protein lysates and IP of effector proteins  
For small-scale infections, ~105 HeLa cells were seeded per well in 24-well plates the day 
before experiment.  Cells were incubated with LGV-L2 or its mutant derivatives at a MOI of 100 
and infections were synchronized by centrifuging at 3000 rpm for 30 min at 10°C, followed by a 
shift to 37°C.  Samples were collected at indicated time points by washing the well once with 
PBS followed by adding 90 µl 2X Laemmli sample buffer. For IPs of effector proteins, ~5x106 
HeLa cells were pre-seeded into a 10-cm cell culture dish the day before infections and cells 
were incubated with LGV-L2 or its mutant derivatives at a MOI of 100.  Infections were 
synchronized by pre-incubation for 1 hour at 4°C in Hanks balanced salt solution, followed by 
the addition of DMEM media pre-warmed to 37°C. At the indicated time points, infected cells 
were washed two times with ice-cold PBS and lyzed in 1 mL Pierce IP lysis buffer supplemented 
with 1 mM PMSF, protease inhibitor cocktail and Halt phosphatase inhibitor (Pierce, Rockford, 
Illinois, USA). After sonication and high speed centrifugation to remove insoluble debris, 
antibodies against TARP (Jorgensen et al., 2011) or TepP were added to cell lysates and 
incubated for 3 hours at 4°C. Protein A resin was added to isolate immunocomplexes, washed 
thoroughly with Pierce IP lysis buffer, and bound proteins were resolved by SDS PAGE and 
subjected to immunoblot analysis. Primary antibodies used in immunoblot include IFIT2 
 59 
antibody (Sigma-Aldrich #SAB1405991), phosphotyrosine (Cell signaling #9411), and Crk (BD 
Transduction Laboratories 610035 clone 22) with 1:1000 dilution in 3% BSA/TBST.  
4.2.4 In vitro GST-Crk binding assay  
Hexahistidine-tagged TepP was purified on Nickel resin (Qiagen, Valencia, CA, USA) and 
beads with bound TepP were aliquoted into three tubes. Two tubes were incubated with HeLa 
cell lysates for in vitro phosphorylation for 1 hour at 4°C and one of the tubes was further 
treated with Alkaline Phosphatase, Calf Intestinal (CIP)(New England BioLabs, Ipswich, MA, USA) 
50 Unit/rxn to reverse phosphorylation reactions at 37°C for 40 min in NEB buffer 3. To prepare 
HeLa cell lysates for in vitro phosphorylation, around 3x106 HeLa cells were lyzed in in vitro 
kinase buffer (100 mM KCl, 10 mM HEPES, pH 7.7, 2 mM MaCl2 and 2 mM ATP) supplemented 
with PMSF, Halt phosphatase inhibitor (Pierce, Rockford, Illinois, USA) and protease inhibitor 
cocktail (Roche, Basel, Switzerland). Cell debris was removed by centrifugation. The last tube 
was incubated with in vitro kinase buffer only as a control. Purified GST and GST-Crk were added 
to tubes containing TepP, phospho-TepP or CIP-treated TepP and incubated in the cold room for 
2 hours.  After washing resins four times with Pierce IP lysis buffer (25 mM Tris, 150 mM NaCl, 1 
mM EDTA, 1 % NP-40, 5 % glycerol; pH 7.4)(Pierce, Rockford, Illinois, USA), bound proteins were 
denatured in sample buffer and analyzed by immunoblots with anti-GST, -Crk, -TepP and -p-Tyr 
antibodies. 
4.2.5 Identification of TepP phosphorylation sites by LC-MS/MS  
IP. Two 15-cm cell culture dishes of confluent HeLa cells were infected with LGVL-2 at a 
MOI of 100 as described above. Another two dishes of confluent HeLa cells were mock-infected. 
Four hours post treatment, cells were collected, washed twice with PBS and lyzed as previously 
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described (Tsai & Carstens, 2006) to generate cytosolic and nuclear/EB fraction. After clarifying 
the cytosolic fraction by high speed centrifugation, antibodies against TepP were added to the 
infected and control cell lysates and incubated for 3 hours at 4°C with continuous mixing.  
Immunocomplexes were purified with protein A resin and bound proteins were solubilized in 
SDS sample buffer.  
 
Phosphopeptide Sample Preparation and Nano-Flow LC-MS/MS Analysis. Following 1D-
SDS-PAGE separation, the molecular weight region corresponding to that of TepP was excised 
and subjected to an in-gel trypsin digestion as previously described (Wilm et al., 1996). Extracted 
peptides were brought to dryness using vacuum centrifugation and resuspended in 100 µL 80 % 
acetonitrile, 1 % TFA, 50 mg/mL MassPrep Enhancer, pH 2.5 (Waters Corp., Milford, Maryland, 
USA). Phosphopeptides were enriched using a 200 µL TiO2 Protea Tip (Protea Bio., Morgantown, 
WV, USA) and subsequently washed with 200 µL 80 % acetonitrile, 1 % TFA, 50 mg/mL MassPrep 
Enhancer followed by 200 µL 80 % acetonitrile, 1 % TFA. Peptides were eluted in 50 µL 20 % 
acetonitrile, 5 % aqueous ammonia, pH 10.5 and then acidified to pH 2.5 with formic acid prior 
to drying using vacuum centrifugation. 
 
Samples were resuspended in 10 µL 2 % acetonitrile, 0.1 % formic acid, 10 mM citric 
acid and subjected to chromatographic separation on a Waters NanoAquity UPLC, in the same 
manner as described for the immunoprecipitation samples, with the following exceptions:  the 
analytical column was held at 5 % B for 5 min at the beginning of the analytical separation, prior 
to a linear elution gradient of 5 % B to 40 % B over 30 min. The analytical column was connected 
to a fused silica PicoTip emitter (New Objective, Cambridge, MA) with a 10 µm tip orifice and 
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coupled to an LTQ-Orbitrap XL mass spectrometer through an electrospray interface. The 
instrument was set to acquire a precursor MS scan in the Orbitrap from m/z 400-2000 with r = 
60,000 at m/z 400 and a target AGC setting of 1e6 ions. In a data-dependent mode of 
acquisition, MS/MS spectra of the three most abundant precursor ions were acquired in the 
linear ion trap with a target AGC setting of 5e3 ions.  Max fill times were set to 1000 ms for full 
MS scans and 250 ms for MS/MS scans with minimum MS/MS triggering thresholds of 5000 
counts.  For all experiments, fragmentation occurred in the LTQ linear ion trap with a collision-
induced dissociation (CID) energy setting of 35% and a dynamic exclusion of 60 s was employed 
for previously fragmented precursor ions. 
 
Qualitative Identifications and residue specific phosphorylation localization from Raw LC-
MS/MS Data. Raw data was processed in Mascot Distiller (v2.3) and searched in Mascot v2.2 
(Matrix Science) against a concatenated database containing the deduplicated entries from 
NCBInr with Chlamydia trachomatis taxonomy.  Search tolerances for LTQ-Orbitrap XL data were 
10 ppm for precursor ions and 0.8 Da for product ions using trypsin specificity with up to two 
missed cleavages.  Carbamidomethylation (+57.0214 Da, C) was set as a fixed modification, 
whereas oxidation (+15.9949 Da, M) and phosphorylation (+79.9663 Da, S, T, and Y) were 
considered a variable modifications.  All searched spectra were imported into Scaffold and 
confidence thresholds were set using the PeptideProphet and ProteinProphet algorithms which 
yielded a peptide and a protein false discovery rate of 0% (Keller et al., 2002; Nesvizhskii et al., 
2003). Phosphorylation site localization was assessed by exporting peak lists directly from 
Scaffold into the online AScore algorithm (ascore.med.harvard.ed)(Beausoleil, Villen, Gerber, 
Rush, & Gygi, 2006). 
 62 
4.2.6 Identification and whole genome sequencing of a TepP-deficient LGV-L2 
strain.  
A strain containing a G309A (W103*) null allele in tepP was initially identified by whole 
genome sequencing of a collection of ethyl methyl sulfonate (EMS)-mutagenized and plaque-
purified C. trachomatis LVG-L2 strains generated as previously described (Nguyen & Valdivia, 
2012)(Bastidas R. J. and Valdivia R. H. unpublished results).  Strain CTL2-M062 harboring tepP 
G309A was identified from a pool of 20 mutants by Sanger sequencing of the tepP locus 
(CTL0255). CTL2-MO62 was recovered in sucrose-phosphate-glutamate (SPG) buffer (0.22 M 
sucrose, 0.01 M potassium phosphate, 0.005 M L-glutamic acid, pH 7.0) after hypotonic lysis of a 
monolayer of infected HeLa cells grown in a 10-cm2 cell culture dish. Lysates were sonicated (2 x 
10 seconds in ice water) and bacterial cells were spun down at 14,000 rpm, for 15 minutes at 4 
°C, and resuspended in 1X DNAse I buffer (New England Biolabs, Ipswich, MA, USA). Cell 
suspensions were treated with 4 Units of DNAse 1 (New England Biolabs, Ipswich, MA, USA) for 
1 hour at 37 °C to deplete contaminating host DNA.  Following a wash with PBS buffer, total 
DNA was isolated with a DNA isolation kit (DNeasy tissue and blood kit, Qiagen, Valencia, CA, 
USA) as described by the manufacturer. 
 
For whole genome sequencing, 1 µg of CTL2-M062 enriched DNA was fragmented with 
an Adaptive Focused Acoustics S220 instrument (Covaris, Inc. Woburn, MA, USA), and DNA 
sequencing libraries were prepared with a library construction kit (TruSeq DNA Sample 
Preparation Kit v2, Illumina, Inc. San Diego, CA, USA) according to the manufacturer’s 
instructions.  Libraries were sequenced in a MiSeq DNA Sequencing Platform (Illumina, Inc. San 
Diego, CA, USA) at the Duke University IGSP DNA Sequencing Core facility. Genome assembly 
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and single nucleotide variant (SNV) identification was performed with Geneious Software 
version 6 (Biomatters - http://www.geneious.com/). The C. trachomatis L2 434/Bu genome 
(GenBank no. NC_010287) was used as reference sequence.  All non synonymous SNVs 
identified in CTL2-M062 (Table 3) were independently verified by Sanger sequencing. 
4.2.7 Generation of Chlamydia Recombinant strains  
Chlamydia recombinants were generated as previously described (Nguyen & Valdivia, 
2012). Briefly, confluent Vero cells grown on a 24-well plate were co-infected with CTL2-MO62 
(Rifampin resistant, RifR) and a Spectinomycin resistant mapping strain (SpcR) at a ratio of 2:4 
and recombinant progeny were selected from among plaques that formed in the presence of Rif 
(200 ng/mL) and Spc (200 μg/mL). Plaque-purified recombinants were further expanded in Vero 
cells and genotyped with SNV specific primers.   
4.2.8 Chlamydia Transformation  
The gene encoding TepP and its predicted promoter region (300 bp upstream of the 
TepP start codon) was amplified by PCR from LGV-L2 genomic DNA and inserted into the E. coli-
Chlamydia shuttle vector p2TK2-SW2 (Agaisse & Derre, 2013).  The recombinant TepPW103* 
strains (G1) were transformed with either empty vector or vector harboring wild type TepP as 
previously described with some modifications (Wang et al., 2011). Briefly, around 4x106 Vero 
cells treated with transformation buffer (10 mM Tris pH 7.4 in 50 mM CaCl2) were infected with 
G1 pre-incubated with around 6 µg plasmid in transformation buffer. Transformed Chlamydia 
was selected under 1U of penicillin G (Sigma P3032) for several passages. After initial selections, 
transformed Chlamydia was maintained in the presence of 10U penicillin G.  TepP expression 
was confirmed by immunoblot analysis. 
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4.2.9 Infectious Forming Unit (IFU) assay  
Confluent monolayers of HeLa cells were infected with various Chlamydia strains at an 
MOI < 1.  Bacteria in infected cells were harvested at 28 hpi by hypotonic lysis as previously 
described (Nguyen & Valdivia, 2013). Serial dilutions of the cell lysates were used to infect a new 
monolayer of HeLa cells and inclusions were detected by immunostaining with anti-Slc-1 
antibodies at 24 hpi.  The number of inclusions was counted under a fluorescence microscope. 
The total number of IFUs obtained at 28h (output) was divided by the number of input bacteria 
to derive number of infectious progeny per input bacteria. 
4.2.10 Crk siRNA knockdowns  
HeLa cells were transfected either with siRNAs designed against Crk (Qiagen Cat. No. 
1027416) or with negative control siRNA (Qiagen Cat. No. 1027280) using Lipofectamine 
RNAiMAX reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA).  At 48 h post transfection, 
cells were harvested and analyzed by immunoblot with anti-Crk and anti-Nup62 (loading 
control) (Mab414, Covance, Princeton, NJ, USA).  For IFU assay, cells were infected with wild 
type LGV-L2 at an MOI < 1 for 28 hr after 48 hr of siRNA transfection. IFU was determined as 
described above. 
4.2.11 Microarray analysis 
Approximately 0.8 x 106 A2EN cells were seeded per well in 6-well plates the day before 
experiment.  Duplicate cells samples  were mock infected, or infected with the tepP mutant 
strain transformed with empty vector or the vector harboring wild type tepP at an MOI of 10.   
Infections were synchronized by centrifugation at 3000 rpm for 30 min at 10°C, followed by an 
immediate shift to 37°C with pre-warmed cell culture media.  Samples were collected at 4 hpi 
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using QIAGEN RNeasy Plus Mini Kit (QIAGEN, Valencia, CA, USA) as described by the 
manufacturer.  RNA integrity was assessed with Agilent 2100 Bioanalyzer G2939A (Agilent 
Technologies, Santa Clara, CA, USA) and quantified with a Nanodrop 8000 spectrophotometer 
(Thermo Scientific/Nanodrop, Wilmington, DE, USA). Hybridization targets were prepared with 
MessageAmp Premier RNA Amplification Kit (Applied Biosystems/Ambion, Austin, TX, USA) from 
total RNA, hybridized to GeneChip Human Genome U133A 2.0 arrays in Affymetrix  GeneChip 
hybridization oven 645, washed in Affymetrix GeneChip  Fluidics Station 450 and scanned with 
Affymetrix GeneChip Scanner 7G according to standard Affymetrix GeneChip Hybridization, 
Wash, and Stain protocols (Affymetrix, Santa Clara, CA, USA). Data analysis was performed using 
Partek Genomic Suite 6.6 (Partek Inc., Saint Louis, MO, USA). 
4.2.12 Quantitative real-time PCR (Q-PCR)  
Q-PCR was performed using Power SYBR Green RNA-to-CT 1-Step Kit and StepOne Real-
Time PCR system as described by the manufacturer (Applied Biosystems, Grand Island, NY, USA). 
Primers specific for IL-6, CXCL3, MAP3k8, IFIT1, IFIT2, and Actin were designed using Roche 
Universal Probe Library (http://www.roche-applied-science.com) and are listed in Appendix 2. 
Primers against Chlamydia 16S rRNA were used to quantify the amount of bacteria in each 
sample (Appendix 2). 
4.2.13 GFP-TepP pulldown  
A stable cell line constitutively expressing GFP-TepP was made using retrovirus packed 
with pLEGFP-C1/TepP. Virus packaging was achieved by co-transfecting GP2-293 cell line 
(Clontech Laboratories, Inc. Mountain View, CA, USA) with both pVSV-G and pLEGFP-C1/TepP 
using FuGENE6 (Promega, Madison, WI, USA). HeLa cells were transduced with virus, followed 
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by 400 µg/mL Geneticin (G418) (Gibco, Life Technologies corp., Grand Island, NY, USA) selection. 
The cell line was further sorted by fluorescence-activated cell sorting (FACS) to enrich GFP-TepP 
expressing cells. Four confluent T175 flasks (around 6 x 107 cells) were used for pull-down. 
Another four T175 flasks of confluent cells expressing GFP alone were used as a control.  Cell 
lysates were incubated with GFP-Trap_A beads (Chromotek, Martinsried, Germany) and bound 
proteins were eluted with 70 µl Pierce elution buffer (pH 2.8) and added with 20 µl 5X Laemmli 
Sample Buffer. Samples were analyzed by SDS page and stained with colloidal blue staining kit 
(Novex, Life Technologies, Carlsbad, CA, USA). Areas between 25 kDa and 188 kDa were sliced 
into five gels for each sample and submitted for mass spectrometry analysis. 
4.2.14 Cell morphology analysis after infection  
Confluent A2EN cells in a 24-well plate were infected with either CTL2-M062G1+pV or 
CTL2-M062G1+pTepP with an MOI of 50 by centrifuging at 3000 rpm for 30 min at 10°C. Images 
for cell morphology were taken 1 hour after shifting to 37°C using DIC (differential interference 
contrast)(Carl Zeiss, Oberkochen, Germany). For immunoblot analysis, samples were collected 
at 8 hpi and probed with anti-TepP, MOMP and actin antibodies. 
 
4.3 Results 
4.3.1 Ct875 (TepP) is translocated early during Chlamydia infection. 
Ct875 is the most abundant Chlamydia-specific hypothetical protein pre-packed in EBs 
(Saka et al., 2011).  As described in the sections below, we renamed Ct875 as TepP to reflect the 
new functions for this protein defined in this study.  Since this protein can be secreted by 
Yersinia T3S system as shown in the previous chapter (Fig. 11), we speculated that this potential 
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T3S effector is secreted early during EB attachment to cells and that it plays a role in invasion 
and/or establishment of the nascent inclusion. Consistent with this, an analysis of Ct875/TepP 
localization by immunofluorescence microscopy indicated a close association of Ct875/TepP 
with EBs by 2 hours post infection (hpi) in HeLa cells (Fig. 12 upper panel).  However, the 
localization of Ct875/TepP was distinct from that of chlamydial LPS, suggesting translocation of 
Ct875/TepP from the EB at attachment sites.  This localization pattern is similar to what has 
been described for TARP and Ct694 (Hower et al., 2009), and is clearly distinct from that of Slc1 
which is mostly localized to the bacterial cytosol (Fig. 12 lower panel).  Overall, these findings 
provide experimental evidence that Ct875/TepP is a new T3S effector translocated early during 
EB entry into epithelial cells. 
 
Figure 12: Ct875/TepP is secreted at Chlamydia entry sites. Ct875/TepP is secreted from EBs 
early during infection. HeLa cells were infected with LGV-L2 at an MOI of 20 for 2 hr.  Cells were 
fixed, permeabilized and immunostained with antibodies against Chlamydia LPS (red), 
Ct875/TepP (green) and Slc1 (green). Scale bar: 1 µm. 
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4.3.2 TepP (Ct875) is phosphorylated upon infection with kinetics distinct from 
TARP. 
Approximately 5-6 distinct proteins are tyrosine-phosphorylated early upon infection 
with C. trachomatis (Birkelund et al., 1994; Fawaz et al., 1997).  Most of these proteins were 
originally assumed to be host proteins that were phosphorylated as a consequence of the 
activation of multiple kinase signaling pathways by Chlamydia, until TARP was identified as one 
of these major tyrosine-phosphorylated proteins (Clifton et al., 2004).   Because Ct875/TepP has 
a molecular weight of 65 kDa, similar to one of the major tyrosine-phosphorylated protein 
detected within 15 min of C. trachomatis LGV-L2 infection (Birkelund et al., 1994)(Fig. 13A), we 
considered the possibility that Ct875/TepP is also tyrosine-phosphorylated.  Consistent with this, 
analysis by indirect immunofluorescence microscopy indicated that anti-Ct875/TepP and anti-
phosphotyrosine signals co-localized around bacteria at 2 hpi (Fig. 13B).  Next, we determined 
that Ct875/TepP immunoprecipitated from infected HeLa cell lysates, but not from EBs lysates, 
was detected by anti-phosphotyrosine antibodies in immunoblot analysis, suggesting that 
Ct875/TepP is tyrosine-phosphorylated upon association with host cells (Fig. 13C).  
Phosphorylation of TepP provided us an opportunity to monitor the kinetics of its translocation 
into cells.  EB infections were synchronized at 4oC and shifted to 37oC for various time intervals 
within a 1 h span.  Infected samples were lysed, split in two and TARP and TepP were 
immunoprecipitated. Total TARP, TepP and tyrosine-phosphorylated protein in the IP material 
was monitored with specific antibodies.   We observed that tyrosine phosphorylation of TepP 
was delayed with respect to TARP by ~10 min (Fig. 13D), suggesting either that kinases 
responsible for TepP phosphorylation are recruited with delayed kinetics to EB entry sites or 
that TARP translocation from EBs precedes TepP.  However, TepP might not be the major ~65-70 
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kDa phosphoprotein since the TepP band only partly overlapped with the major ~65-70 kDa 
phosphotyrosine protein bands in dual labeling immunoblots (Fig. 13E). 
 
We proceeded to map the phosphorylation sites on translocated Ct875/TepP by mass 
spectrometry.  Infections were scaled up and Ct875/TepP was IP at 4 hpi in the presence of 
phosphatase inhibitors and processed for phospho-proteomics analysis.  Four phospho-peptides 
were detected in the sample: two contained phosphorylated tyrosine (Y43 and Y496) and two 
phosphorylated serine residues (S410 and S415) (Fig. 14). Because the peptide spanning Y496 is 
part of a tandem repeat (ASDYDLPR), it is unclear if one or both tyrosine residues (Y496 and 
Y504) are phosphorylated.  Overall, these results indicate that Ct875/TepP is phosphorylated at 





Figure 13: TepP/Ct875 is phosphorylated upon translocation. A) Immunoblot analysis of total 
cell lysates of Chlamydia infected cells shows the appearance of at least three major tyrosine-
phosphorylated proteins (>150 kDa, 100 kDa, and 65-70 kDa) within 1 hpi. B) TepP colocalizes 
with anti-phospho-Tyr signals at Chlamydia entry sites.  HeLa cells were infected as in A) and 
immunostained with anti-TepP (green) and anti-p-Tyr (red) antibodies.  Host and bacterial DNA 
were stained with DAPI (blue). Scale bar: 10 µm (upper panel); 2 µm (lower panel). C) TepP is 
phosphorylated at tyrosine residues upon EB association with host cells.  Cells were infected as 
in A) with an MOI of 100 for the indicated times and TepP was immunoprecipitated from cell 
lysates and analyzed by immunoblotting with anti-TepP and anti p-Tyr antibodies. TepP was 
recognized by anti p-Tyr antibodies only upon association with host cells. D-E) TARP and TepP 
are tyrosine-phosphorylated at different rates during Chlamydia infection. HeLa cells were 
infected as in A) and total protein lysates were generated at 0, 5, 15, 30 min and 1 hpi and TepP 
and TARP was IP as above with anti-TARP or anti-TepP antibodies followed by immunoblot 
analysis with anti-TARP, -TepP and p-Tyr antibodies (D).  Note there is a relative delay in TepP 
tyrosine phosphorylation with respect to TARP.  The prominent higher molecular weight 
tyrosine-phosphorylated band corresponds to Tarp, as assessed by 2-color 
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immunofluorescence-detection.  In contrast, TepP only partially overlaps with the major 65-70 




Figure 14: M/Z spectra of TepP phosphopeptides. Endogenous TepP was immunoprecipitated 
at 4 hpi. The corresponding TepP band was excised from the gel, digested with trypsin and 
phosphopeptides were enriched on a titanium dioxide affinity column, prior to elution and 
analysis by LC-MS/MS. Four phospho-peptides were detected: two phosphoserine and two 
phosphotyrosine. Detected peptides were shown above each spectrum and detected 
phosphorylation site was underlined. Y-axis is the relative intensity of peaks. X-axis is mass-to-
charge ratio (m/z). 
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4.3.3 Crk, an adaptor protein, associates with TepP and is recruited to nascent 
inclusions. 
Protein tyrosine phosphorylation plays an important role in signal transduction by 
mediating the recruitment of proteins containing Src homology 2 (SH2) and/or phosphotyrosine 
binding (PTB) domains to target proteins (Backert & Selbach, 2005). Analysis of the TepP 
phosphopeptides using NetPhorest (http://netphorest.info/) (Miller et al., 2008) indicated the 
presence of a consensus pYxxP binding site (ASDYDLPR) for the scaffolding protein Crk (Fig. 15A) 
(Songyang et al., 1993). Crk is an adaptor protein that mediates phosphorylation-mediated 
regulation of cytoskeletal dynamics, cell adhesion and migration, phagocytosis, immune 
response and tumorogenesis (Birge, Kalodimos, Inagaki, & Tanaka, 2009; Liu, 2013). Mammals 
express Crk-I and Crk-II, two alternatively spliced forms of CRK, and the Crk-like protein, Crk-L.  
Crk proteins contain SH2 and SH3 domains, which mediate binding to phosphorylated tyrosine 
residues and proline-rich domains, respectively (Birge et al., 2009). To test if TepP translocated 
by EBs associated with Crk proteins, we performed a time course of infection and 
immunoprecipitated TepP in the presence of phosphatase inhibitors.  Chlamydia infection did 
not alter the steady state levels of CrkI-II (Fig. 15E); whereas increasing amounts of CrkI and CrkII 
co-IP with TepP as the infection progressed (Fig. 15B), indicating that these proteins are part of a 
complex.  By immunofluorescence microscopy, we further observed endogenous Crk recruited 
to bacteria as early as 1 hpi and that this association continued past 8 hours, a point at which 
nascent inclusions have migrated to the microtubule organizing center (Fig. 15C).  To test if the 
association of TepP with Crk is direct, we next examined if recombinant TepP could bind to Crk 
in vitro.  We found that the binding between TepP and GST-Crk was significantly enhanced by in 
vitro phosphorylation of TepP and reduced after phosphatase treatment (Fig. 15D), suggesting 
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that TepP phosphorylation is important for the recruitment of Crk.  Together, these data are 
consistent with a model wherein TepP, after being secreted into host cells, is tyrosine-
phosphorylated and recruits Crk to nascent inclusions, presumably through interactions with its 
SH2 domain. 
 
Figure 15: Crk-I and Crk-II bind to tyrosine-phosphorylated TepP and are recruited to nascent 
inclusions early during infection. A) Cartoon schematic of TepP phosphorylation sites identified 
by mass spectrometry (Fig. 14). B) CrkI and CrkII co-IP with TepP. HeLa cells were infected with 
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L2 at MOI of 100 for 1, 2, 4, 6 and 8 hours. Cell lysates were immunoprecipitated with anti-TepP 
antibodies and the bound proteins were analyzed by immunoblot with anti-Crk, TepP and p-Tyr 
antibodies. Both isoforms of Crk, CrkI (lower band) and CrkII (upper band), co-IP with TepP. 
Uninf-uninfected. C) CrkI-II is recruited to Chlamydia entry sites and nascent inclusions. HeLa 
cells were infected with L2 at an MOI of 20 for 1 and 8 hours. Cells were fixed and stained with 
anti-MOMP (green) and anti-Crk (red) antibodies.  Left panels are magnified images form boxed 
areas.  Examples of sites of association between bacteria and Crk are marked by arrows.  DAPI 
was used to stain nucleic acids. CrkI-II was recruited to Chlamydia entry sites by 1 hpi and this 
association continued after the nascent inclusion had trafficked to the host cells’ perinuclear 
region. D) Recombinant TepP interacts with GST-Crk in a phosphorylation-dependent manner. 
Purified GST or GST-Crk was incubated with purified TepP-6xHis or purified TepP-6xHis that had 
been phosphorylated in vitro.  One sample of phosphorylated TepP-6xHis was treated with Calf 
intestinal Alkaline Phosphatase (PPase).  The efficiency of TepP co-precipitation with GST-Crk 
increased after in vitro phosphorylation.  Dephosphorylation with PPase decreased the 
efficiency of GST-Crk co-precipitation. E) Crk levels remain constant throughout infection. 
Confluent monolayer of HeLa cells were infected with wild type LGV-L2 at an MOI of 50 and 
collected at indicated time points. Samples were subjected to immunoblot analysis with 
antibodies against Crk, Actin and MOMP. Uninf: control uninfected cells. 
 
4.3.4 TepP is required for the recruitment of Crk to nascent inclusions 
Although Chlamydia spp. lacks a system for performing targeted gene disruptions, 
chemically-derived mutants can be readily generated and loss-of-function mutations can be 
identified by whole genome sequencing (Nguyen & Valdivia, 2012).  Using such an approach, our 
group has recently generated and sequenced a comprehensive collection of ethyl methyl 
sulfonate (EMS)-derived mutants of C. trachomatis LGV-L2 (unpublished results).  We identified 
6 strains with mutations in TepP, including strain CTL2-M062, bearing a G to A transversion that 
led to a premature stop codon at amino acid 103 (W103*) (Fig. 16A). By immunoblot analysis, 
EBs from CTL2-M062 lacked any detectable full length TepP, suggesting that the truncated form 
of TepP was either unstable or not properly expressed (Fig. 16B).  Interestingly, even though 
TepP is not the predominant ~65-70 kDa tyrosine-phosphorylated protein observed early during 
C. trachomatis infection, these phosphorylated species were no longer detected when cells 
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were infected with the TepP-deficient CTL2-M062 mutant (Fig. 16C); whereas the levels of the 
phospho-TARP band (~150 kDa) were unaltered.  These results indicate that TepP may induce 
the phosphorylation of additional host and or secreted bacterial proteins at the early stages of 
infection.  Next, we determined whether Crk association with nascent inclusions was dependent 
on TepP.  HeLa cells were infected with either wild type or the TepP-deficient C. trachomatis 
mutant and the co-localization of bacteria with Crk was assessed by immunofluorescence 
microscopy.  Crk was no longer associated with intracellular CTL2-M062 by 8 hpi (Fig. 16D).   
 
The original TepP deficient isolate carried an additional 11 EMS-induced single 
nucleotide variants (SNVs) (Fig. 16A; Table 3) (Whole genome sequencing was performed by Dr. 
Robert Bastidas). To exclude the possibility that these SNVs contributed to the lack of Crk 
recruitment to nascent inclusions, we generated recombinant strains between the TepP 
deficient isolate (generated in a RifR background) and a spectinomycin (SpcR) LGV-L2 strain by 
co-infection of cells as previously described (Nguyen & Valdivia, 2012).   Double drug resistant 
recombinants were plaque purified and screened by allele-specific PCR to determine the relative 
segregation of mutations present in the original TepP-deficient isolate. A total of 200 
recombinants were screened and four co-isogenic strains were identified where various 
assortment of mutations were present (Fig. 17A and 17B). The marked reduction of the ~65-70 
kDa signal in phosphotyrosine immunoblots was only observed in the strain lacking TepP (Fig. 
17C).  Similarly, Crk recruitment to nascent inclusions was only impaired in strains encoding the 
TepPW103* variant (Fig. 17D), providing further genetic support to the notion that TepP is directly 
responsible for the recruitment of Crk to inclusions. 
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Figure 16: A TepP mutant failed to recruit Crk to nascent inclusions. A) Physical map of single 
nucleotide variants identified in strain CTL2-M062, a chemically derived LGV-L2 mutant 
containing a nonsense mutation in the codon for amino acid 103 of TepP.  Non synonymous 
mutations were identified by whole genome sequencing and verified by Sanger sequencing. Key 
differences from the parental reference strain are highlighted. B-C) TepP is required for the 
accumulation of major tyrosine-phosphorylated proteins in Chlamydia infected cells.  
Immunoblot analysis of the EB lysate of CTL2-M062 showed no detectable levels of TepP 
compared to wild type LGV-L2 (WT) (B).  HeLa cells were infected with wild type LGV-L2 (WT) or 
CTL2-M062 at an MOI of 50 and samples were collected at indicated time points and analyzed 
by immunoblot with antibodies against p-Tyr and MOMP.  MOMP (Chlamydia major outer 
membrane protein) is a loading control for bacteria loads.  Arrows indicate major TepP-
dependent tyrosine-phosphorylated proteins (C).  D) Crk does not associate with nascent 
inclusions in CTL2-M062 infected cells.  Immunofluorescence staining of HeLa cells infected with 
wild type LGV-L2 and CTL2-M062 for 8 h. Cells were stained with anti-Crk (red) and anti-MOMP  
(green) antibodies, and with DAPI (blue).  Crk recruitment was absent in a TepP deficient strain. 
Scale bar: 20 µm. 
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Figure 17: TepP is required for the recruitment of Crk to nascent inclusions. A) Genotype of 
recombinant strains harboring products of a CTL2-M062 (Rifr) and a LGV-L2 Spcr co-infection. 
Black shading indicates single nucleotide variants (SNV) present in CTL2-M062. Each SNV was 
verified by Sanger sequencing. B) C. trachomatis recombinant harboring a tepP null allele (tepP 
W103*) does not express full length TepP. EBs of four recombinants were selected from a co-
infection setting between CTL2-M062 (Rifr) and a Spcr LGV-L2 variant.  Recombinants were 
isolated by plaquing on Vero cell monolayers in the presence of rifampin and spectinomycin.  
Individual plaques were amplified on Vero cells, and EBs from recombinants with the genotypes 
shown were harvested and purified on density gradients.  EBs were lyzed in SDS sample buffer, 
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and subjected to immunoblot analysis with antibodies against TepP and RpoB/B’, MOMP and 
Slc1.  C-D) The tepP mutation is genetically linked to the lack of the infection-induced p65-70 
kDa tyrosine-phosphorylated proteins and the loss of Crk recruitment to nascent inclusions. 
Various recombinant strains generated from a cross between CTL2-M062 and wild type LGV-L2 
were tested for the presence of the p65-70 kDa p-Tyr proteins (C) and recruitment of Crk to 




























84,969 G A G514A G172R Non synonymous secA CTL0070  CT701 
preprotein translocase 
subunit SecA 523 58% 100% 
145,291 G A G1797A   Synonymous   CTL0113  CT744 hypothetical protein 462 60% 100% 
192,335 C T G2187A   Synonymous priA CTL0147  CT778 
primosome assembly 
protein PriA 556 50% 100% 
192,335 C T C1128T   Synonymous bioF CTL0146  CT777 
8-amino-7-oxononanoate 
synthase 556 50% 100% 
c216,843 C T    Non coding         616 50% 99% 
320,638 G A C737T S246F Non synonymous pmpI CTL0254  CT874 
polymorphic outer 
membrane protein 386 51% 100% 
321,957 G A G309A W103* Non sense tepP CTL0255  CT875 
translocated early 
phospho protein 328 51% 100% 
331,833 G A G213A M71I Non synonymous   CTL0264  CT009 hypothetical protein 470 57% 100% 
335,058 G A G528A   Synonymous   CTL0267  CT012 
putative integral 
membrane protein 613 54% 100% 
444,524 C T C1650T   Synonymous   CTL0360  CT105 hypothetical protein 604 51% 100% 
458,498 C T C230T T77I Non synonymous incF CTL0372  CT117 
inclusion membrane 
protein F 553 51% 100% 
480,180 G A G480A   Synonymous   CTL0395  CT140 exported protein 474 53% 99% 
514,164 C T G521A   Synonymous   CTL0425  CT140 hypothetical protein 659 50% 100% 
537,203 C T G541A V181I Non synonymous mgtE CTL0446  CT194 
magnesium transport 
protein 569 53% 100% 
558,011 C T C1153T   Synonymous hemL CTL0462  CT210 
glutamate-1-
semialdehyde 
aminotransferase 566 53% 100% 
561,426 G A C185T P62L Non synonymous   CTL0466  CT214 hypothetical protein 490 65% 99% 
564,595 G A G128A G43D Non synonymous   CTL0469  CT217 hypothetical protein 486 52% 100% 
604,651 C T C471T   Synonymous   CTL0506  CT254 inner membrane protein 676 53% 100% 
689,168 G A G423A   Synonymous xseA CTL0583  CT329 
exodeoxyribonuclease VII 
large subunit 572 58% 100% 
709,387 G A C140T A47V Non synonymous rpsU CTL0596  CT342 30S ribosomal protein S21 496 58% 100% 
726,889 C T G717A   Synonymous   CTL0610  CT356 hypothetical protein 393 55% 100% 
826,893 C T G243A   Synonymous rpsL CTL0698  CT439 30S ribosomal protein S12 529 51% 100% 
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827,957 G A G85A D29N Non synonymous tsp CTL0700  CT441 
carboxy-terminal 
processing protease 509 51% 100% 
846,119 C T C567T   Synonymous plsC CTL0713  CT453 
1-acyl-sn-glycerol-3-
phosphate acyltransferase 521 60% 99% 
884,316 G A C458T S153L Non synonymous glgC CTL0750  CT489 
glucose-1-phosphate 
adenylyltransferase 660 50% 100% 
951,432 G A G408A M136I Non synonymous   CTL0823  CT560 hypothetical protein 459 55% 100% 
123,163 C A C -> A   Non coding         423 52% 100% 
127,338 T A T657A   Synonymous   CTL0103  CT734 putative lipoprotein 369 54% 100% 
435,453 G A C743T A248V Non synonymous nusA CTL0352  CT097 
transcription elongation 
factor NusA 630 55% 100% 
448,523 G A C110T A37V Non synonymous   CTL0364  CT109 hypothetical protein 587 65% 100% 
616,827 C T G315A   Synonymous   CTL0518  CT266 hypothetical protein 616 52% 100% 
637,039 C T C610T R204C Non synonymous clpC CTL0538  CT286 
ATP-dependent Clp 
protease 698 54% 100% 
638,353 T C T1924C F642L Non synonymous clpC CTL0538  CT286 
ATP-dependent Clp 
protease 548 56% 100% 
675,519 G§ A§ C1411T H471Y Non synonymous rpoB CTL0567  CT315 
DNA-directed RNA 
polymerase subunit beta 585 51% 100% 
693,265 G A G473A S158N Non synonymous pykF CTL0586  CT332 pyruvate kinase 649 51% 100% 
798,820 G A G470A G157E Non synonymous pmpC CTL0671  CT414 
polymorphic outer 
membrane protein 600 56% 100% 
929,717 C A C -> A   Non coding         544 53% 100% 
         *Single nucleotide variants in black are variants identified in CTL2M062. 
         *Single nucleotide variants in gray are strain background variants differing from 434/Bu reference sequence.  
             § Variant leading to rifampin resistance. 




4.3.5 Complementation of the TepP mutant restores the pattern of tyrosine                        
phosphorylation induced by Chlamydia and rescue Crk recruitment  
Finally, to provide final genetic confirmation of the role of TepP in mediating these 
events, we took advantage of recent developments in DNA transformation in C. trachomatis 
(Wang et al., 2011).  We transformed the recombinant TepPW103* strain with a C. trachomatis-E. 
coli shuttle plasmid expressing the tepP gene under the control of its endogenous promoter or 
the empty vector control and selected for stable transformants in the presence of penicillin.  The 
transformed strains expressed TepP to a similar level as wild type strains (Fig. 18A).  An 
immunoblot analysis of infected cells showed the restoration of the ~65-70 kDa 
phosphotyrosine immunosignals in TepP complemented strains but not in strains transformed 
with the empty vector (Fig. 18B).  In addition, Crk recruitment to nascent Chlamydia inclusions 
was restored (Fig. 18C).  Similar results were observed when using A2EN cells, a newly derived 
human endocervical epithelial cell line (Buckner et al., 2011) (Fig. 18D and 18E).  Taken together, 
our results confirm that TepP is the major contributor, either directly or indirectly, to the 
tyrosine-phosphorylation of multiple proteins early during C. trachomatis infection and the 




Figure 18: Genetic complementation of a Chlamydia tepP mutant restores the normal 
tyrosine-phosphorylation pattern of multiple proteins and rescues Crk recruitment to nascent 
inclusions. A) The recombinant TepPW103* strain CTL2-M062G1 was transformed with an empty 
vector (Vec.) or a vector harboring the wild type tepP gene (pTepP).  Immunoblot analysis of EBs 
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derived from these strains with anti-TepP antibodies confirmed the complementation of TepP 
expression to wild type levels (LGV-L2).  Slc1 and RpoB/B’ levels were shown as loading controls.  
B) The complemented recombinant TepPW103* strains restored the pattern of tyrosine-
phosphorylation induced during Chlamydia infection. Confluent HeLa cells were infected with 
CTL2-M062G1 strains described in (A) at an MOI of 50 and total protein lysates were collected at 
indicated time points. Samples were subjected to immunoblot analysis with antibodies against 
p-Tyr and MOMP. C) The complemented recombinant TepPW103* strain rescued Crk recruitment 
to nascent Chlamydia inclusions.  HeLa cells were infected for 8 h with CTL2-M062G1 strains 
described in (A) at an MOI of 20, and immunostained with anti-Crk (red) and anti-MOMP (green) 
antibodies, and DAPI (blue). D-E) Similar results were observed in A2EN cells, a newly derived 
human endocervical epithelial cell line. 
4.3.6 TepP and Crk are not essential for Chlamydia growth in Tissue culture 
model. 
Although the CTL2-M062 had a ~ 15 fold growth defect compared to the wild type 
parental strain, we could not unambiguously link this growth defect to strains bearing the tepP 
mutant allele (data not shown).   To address whether TepP played a role in promoting C. 
trachomatis replication or infectivity, we compared the ability of the tepP mutants transformed 
with the tepP expressing plasmid or plasmid alone to generate infectious progeny.  We observed 
no differences in the generation of EBs among these strains in either HeLa cells (Fig. 19D) or in 
A2EN cells (data not shown).   Similarly, silencing of Crk, a major TepP-binding partner, with 
siRNAs in HeLa cells did not impact C. trachomatis replication (Fig. 19A-C). 
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Figure 19: Replication potential of LGV-L2 in Crk knockdown cells and tepP mutants in 
epithelial cells. A) Transfection of Crk siRNAs decreased the expression level of both CrkI and 
CrkII in HeLa cells. Upper panel is the immunoblot analysis of HeLa cells transfected with two 
different Crk siRNAs (3 and 5) or negative control siRNA (NC) for 48 h. Total cell lysates were 
probed with anti-Crk and anti-Nup62 (loading control) antibodies. B) Quantification of siRNA-
mediated decreased levels of Crk protein expression as assessed by quantitative immunoblots 
on a LI-COR imager. CrkI and CrkII expression level was decreased around 50% after siRNA 
treatment.  C) Crk siRNA knockdown does not affect C. trachomatis growth as assessed by IFU 
assay. IFUs were normalized to growth in cells treated with control siRNA (NC).  D) Comparison 
of IFU burst between the tepP mutant CTL2-MO62G1, and its derivatives transformed with 
empty vector or pTepP. HeLa cells were infected for 28 h at an MOI < 1.  The resulting infectious 
progeny were titered in HeLa cells as described in Material and Methods, and normalized to 
input number of bacteria. All data shown were as means ± standard deviations from 
experiments performed in triplicate. 
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4.3.7 TepP regulates the expression of genes associated with innate immune 
responses. 
These observations suggest that TepP is not essential for C. trachomatis replication in 
cell culture models of infection, although we cannot rule out a role for TepP in promoting 
invasion or intracellular survival in other cell types or in the context of intact tissues and an 
active immune system.  However, given the observation that TepP recruits Crk, a scaffolding 
protein important in cell signaling and TepP mediates multiple tyrosine phosphorylations, we 
hypothesized that the presence of TepP should lead to defined transcriptional response by the 
infected cell.  We compared the global transcriptional profile of mock infected A2EN cells or 
A2EN cells infected with the tepP mutant and its complemented counterpart for 4 h (RNA 
samples were collected by Victoria Carpenter).  A microarray analysis revealed 33 genes 
displaying greater than 1.5 fold changes in gene expression levels (Fig. 20A and Table 3).  A Gene 
Ontology (GO) analysis of these differentially expressed genes revealed an enrichment for genes 
with immunity-related functions (data not shown). We next validated by quantitative-PCR, the 
expression of five of these genes: IL-6 and CXCL3, and MAP3k8, IFIT1 and IFIT2, whose mRNA 
levels decrease and increase, respectively, depending on the presence of TepP (Fig. 20B).  
Interestingly, the fold-change for IFIT1 and IFIT2 changed from 2 fold to more than 10 fold by 8 
hpi; whereas the level of fold-change for MAP3k8 did not (Fig. 20C).  The change in transcript 
levels also reflected in protein levels. IFIT2 protein was detected 24 hpi and this induction was 
TepP-dependent, as shown by immunoblot of Chlamydia infection time course probed with anti-
IFIT2 antibody (Fig 20D).  These data suggest that one of the functions of TepP is to modulate 
gene expression in the early stages of infection, presumably to impact the type and magnitude 
of the ensuing innate immune response. 
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Figure 20: Global transcriptional profiling links TepP function to immune-related responses. A) 
Microarray analysis identified 33 host genes that have >1.5 fold-change in transcript levels 
between recombinant TepPW103* strains (CTL2-M062G1) transformed with empty vector (Vec) 
and vector containing wild type tepP gene (pTepP).  A2EN epithelial cells were infected for 4 h. 
Results shown were from duplicate biological samples.  B) Q-PCR results validated transcript 
level changes observed for 5 immune-related genes at 4 hpi.  Fold-change in mRNA abundance 
was normalized to CTL2-M062G1 (Vec).  The amount of bacteria in each sample is indicated by 
16S rRNA. C) TepP-dependent elevation of IFIT transcript levels at 8 hpi.  Q-PCR results of 
MAP3k8, IFIT1 and IFIT2 mRNA in A2EN cells infected as in (A).  All data shown were as means ± 
standard deviations from three independent biological replicates. *, P < 0.05; **, P < 0.01; ***, P 
< 0.001 (one-way analysis of variance and Tukey’s multiple-comparison test). D) IFIT2 protein 
levels increased in a TepP-dependent manner during Chlamydia infection. A2EN epithelial cells 
were infected with CTL2-M062G1 transformed with empty vector (Vec) and vector containing 
wild type tepP gene (pTepP) at an MOI of 10.  Samples were collected at indicated time points 
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and analyzed by immunoblot with antibodies against IFIT2, Actin and MOMP. Actin is a loading 









Table 4: List of genes in A2EN cells that display greater than 1.5 fold change in transcription upon infection with the tepP mutant vs its 
complemented counterpart at 4 hpi. 
         
































vs. V Description 
204794_at DUSP2 
dual specificity 
phosphatase 2 NM_004418 0.001 1.531 
V up vs 
TepP 0.003 1.263 
Uninf up vs 





with thrombospondin type 
1 motif, 1 NM_006988 0.001 1.726 
V up vs 
TepP 0.021 1.173 
Uninf up vs 





kinase kinase kinase 8 NM_005204 0.002 -1.857 
V down vs 
TepP 0.001 -2.244 
Uninf down 




A kinase (PRKA) anchor 
protein (yotiao) 9 NM_005751  0.001 -1.544 
V down vs 
TepP 0.006 -1.301 
Uninf down 
vs TepP 0.019 1.186 
Uninf up vs 
V 
209101_at CTGF 
connective tissue growth 
factor NM_001901 0.001 1.562 
V up vs 
TepP 0.015 1.213 
Uninf up vs 




tumor necrosis factor 
(ligand) superfamily, 
member 10 NM_003810 0.003 -1.709 
V down vs 
TepP 0.002 -1.848 
Uninf down 




chemokine (C-X-C motif) 
ligand 3 NM_002090 0.003 1.570 
V up vs 
TepP 0.465 -1.041 
Uninf down 





(decycling) 1 NM_002133 0.003 -1.739 
V down vs 
TepP 0.003 -1.783 
Uninf down 
vs TepP 0.721 -1.025 
Uninf down 
vs V 
202364_at MXI1 MAX interactor 1 NM_005962 0.004 -1.763 
V down vs 
TepP 0.003 -1.910 
Uninf down 






repeats 2 NM_001547 0.004 -1.682 
V down vs 
TepP 0.003 -1.768 
Uninf down 




TBC1 domain family, 
member 8 (with GRAM 
domain) NM_007063 0.004 -1.603 
V down vs 
TepP 0.004 -1.576 
Uninf down 
vs TepP 0.776 1.018 
Uninf up vs 
V 
215599_at 
GUSBP3 /  
GUSBP9 
glucuronidase, beta 
pseudogene 3 / 
glucuronidase, beta 
pseudogene 9 NR_027386 0.003 -1.636 
V down vs 
TepP 0.009 -1.412 
Uninf down 
vs TepP 0.079 1.159 
Uninf up vs 
V 
214657_s_at LOC100653017  uncharacterized NR_002802 0.004 -1.808 V down vs 0.008 -1.596 Uninf down 0.198 1.133 Uninf up vs 
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/ MIR612 / 
NEAT1 
LOC100653017 / microRNA 
612 / nuclear paraspeckle 
assembly transcri 
TepP vs TepP V 
209102_s_at HBP1 
HMG-box transcription 
factor 1 NM_012257 0.008 -1.577 
V down vs 
TepP 0.005 -1.759 
Uninf down 




PTPRF interacting protein, 
binding protein 2 (liprin 
beta 2) NM_003621 0.008 -1.756 
V down vs 
TepP 0.010 -1.678 
Uninf down 
vs TepP 0.640 1.047 
Uninf up vs 
V 
207069_s_at SMAD6 SMAD family member 6 NM_005585 0.007 -1.517 
V down vs 
TepP 0.012 -1.406 
Uninf down 
vs TepP 0.310 1.079 
Uninf up vs 
V 
219995_s_at ZNF750 zinc finger protein 750 NM_024702 0.009 -1.603 
V down vs 
TepP 0.019 -1.437 
Uninf down 
vs TepP 0.254 1.115 
Uninf up vs 
V 
216015_s_at NLRP3 
NLR family, pyrin domain 
containing 3 NM_004895 0.008 1.525 
V up vs 
TepP 0.051 1.236 
Uninf up vs 




GULP, engulfment adaptor 
PTB domain containing 1 NM_016315 0.013 -1.505 
V down vs 
TepP 0.013 -1.505 
Uninf down 
vs TepP 0.999 1.000 
Uninf up vs 
V 
211834_s_at TP63 tumor protein p63 NM_001114978 0.008 1.514 
V up vs 
TepP 0.047 1.246 
Uninf up vs 




nuclear receptor subfamily 
4, group A, member 2 NM_006186 0.034 1.985 
V up vs 
TepP 0.441 -1.179 
Uninf down 




nuclear receptor subfamily 
4, group A, member 2 NM_006186 0.007 1.965 
V up vs 
TepP 0.143 -1.221 
Uninf down 




nuclear receptor subfamily 
4, group A, member 2 NM_006186 0.041 1.741 
V up vs 
TepP 0.073 -1.544 
Uninf down 





44 NM_006417 0.010 -1.847 
V down vs 
TepP 0.024 -1.550 
Uninf down 
vs TepP 0.189 1.192 
Uninf up vs 
V 
219312_s_at ZBTB10 
zinc finger and BTB domain 
containing 10 NM_023929 0.017 -1.627 
V down vs 
TepP 0.015 -1.675 
Uninf down 




GULP, engulfment adaptor 
PTB domain containing 1 NM_016315 0.014 -1.576 
V down vs 
TepP 0.020 -1.496 
Uninf down 
vs TepP 0.599 1.053 
Uninf up vs 
V 
206843_at CRYBA4 crystallin, beta A4 NM_001886 0.017 1.562 
V up vs 
TepP 0.032 1.424 
Uninf up vs 





135kDa NM_014645 0.020 -1.572 
V down vs 
TepP 0.026 -1.513 
Uninf down 
vs TepP 0.727 1.039 





homolog (avian) NM_005360 0.026 -1.619 
V down vs 
TepP 0.024 -1.645 
Uninf down 





dehydrogenase 15-(NAD) NM_000860 0.021 -2.021 
V down vs 
TepP 0.032 -1.820 
Uninf down 
vs TepP 0.556 1.110 




dehydrogenase 15-(NAD) NM_000860 0.049 -1.984 
V down vs 
TepP 0.051 -1.969 
Uninf down 
vs TepP 0.974 1.008 





GTP binding protein 
overexpressed in skeletal 
muscle NM_005261 0.042 1.585 
V up vs 
TepP 0.357 -1.157 
Uninf down 
vs TepP 0.020 -1.834 
Uninf down 
vs V 
205587_at FGFR1OP FGFR1 oncogene partner NM_007045 0.019 1.528 
V up vs 
TepP 0.077 1.274 
Uninf up vs 






repeats 1 NM_001548 0.050 -1.510 
V down vs 
TepP 0.029 -1.669 
Uninf down 




interleukin 6 (interferon, 
beta 2) NM_000600 0.050 2.017 
V up vs 
TepP 0.485 -1.192 
Uninf down 




ribosomal protein S6 
kinase, 90kDa, polypeptide 
5 NM_004755 0.037 -1.596 
V down vs 
TepP 0.044 -1.547 
Uninf down 
vs TepP 0.827 1.032 




factor 2 NM_001256090 0.049 -1.560 
V down vs 
TepP 0.196 -1.257 
Uninf down 
vs TepP 0.216 1.241 
Uninf up vs 
V 
                   
                       aprobeset ID on Affymetrix human genome U133A 2.0 array 
                       bp-value was calculated using ANOVA analysis 
                       cV- CTL2-M062G1 transformed with empty vector 
                       d TepP- CTL2-M062G1 transformed with vector containing wild type tepP gene 
                       eUninf - uninfected A2EN cells
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4.3.8 GFP-TepP pull down multiple actin-related proteins 
Protein homology searches and functional domain predictions revealed limited 
information for TepP. To decipher the function of TepP, we decide to identify the potential 
interacting partners in host cells using GFP IP followed by mass spectrometry.  To obtain enough 
material for mass spectrometry analysis, we constructed a stable HeLa cell line that 
constitutively expressed GFP-TepP and enriched GFP-TepP by GFP-Trap, a GFP-binding protein 
crosslinked agarose beads. The same procedure was performed on a stable HeLa cell line that 
expressed GFP as a control. Interestingly, multiple proteins involved in actin cytoskeletal 
dynamics were specifically detected in the GFP-TepP sample, indicating that TepP could 
modulate host actin cytoskeletal rearrangements (Table 5). 
 
Table 5: Number of unique spectruma identified by LC-MS/MS from samples 
immunoprecipitated with GFP-Trap from cell lysate containing GFP or GFP-TepP. 
      
 
  IP Sample 




(kDa) Taxonomy GFP 
GFP-
TepP 
1 Caldesmon (CALD1) Q05682|CALD1   93 Human 0 15 
2 Tropomyosin beta chain (TPM2) P07951|TPM2   33 Human 0 15 
3 Myosin-10 (MYH10) P35580|MYH10   229 Human 0 12 
4 Fascin (FSCN1) Q16658|FSCN1   55 Human 0 11 
5 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) P04406|G3P   36 Human 0 8 
6 
2-oxoglutarate dehydrogenase E1 component, 
mitochondrial (OGDH) Q02218|ODO1   116 Human 0 9 
7 Phostensin (KIAA1949) Q6NYC8|PHTNS   68 Human 0 7 
8 Plastin-3 (PLS3) P13797|PLST   71 Human 0 7 
9 
Conserved hypothetical protein Ct875 (TepP) 
[Chlamydia trachomatis 434/Bu] gi|165930209 66 C. trachomatis 0 7 
10 Ankycorbin (RAI14) Q9P0K7|RAI14   110 Human 0 6 
11 Histone deacetylase 6 (HDAC6) Q9UBN7|HDAC6   131 Human 0 5 
12 Erythrocyte band 7 integral membrane protein (STOM) P27105|STOM   32 Human 0 5 
13 Prohibitin-2 (PHB2) Q99623|PHB2   33 Human 0 5 
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14 Junction plakoglobin (JUP) P14923|PLAK   82 Human 0 5 
15 Aminopeptidase N (ANPEP) P15144|AMPN   110 Human 0 5 
16 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 (GNB2) P62879|GBB2   37 Human 0 3 
17 Brain acid soluble protein 1 (BASP1) P80723|BASP1   23 Human 0 4 
18 EF-hand domain-containing protein D2 (EFHD2) Q96C19|EFHD2   27 Human 0 4 
19 A-kinase anchor protein 2 (AKAP2) Q9Y2D5|AKAP2   95 Human 0 4 
20 
Guanine nucleotide-binding protein G(i), alpha-2 
subunit (GNAI2) P04899|GNAI2   40 Human 0 4 
21 L-lactate dehydrogenase B chain (LDHB) P07195|LDHB   37 Human 0 4 
22 
Voltage-dependent anion-selective channel protein 1 
(VDAC1) P21796|VDAC1   31 Human 0 3 
23 Dolichol-phosphate mannosyltransferase (DPM1) O60762|DPM1   30 Human 0 3 
24 F-actin-capping protein subunit alpha-2 (CAPZA2) P47755|CAZA2   33 Human 0 3 
25 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial (DLST) P36957|ODO2   49 Human 0 3 
26 PDZ and LIM domain protein 7 (PDLIM7) Q9NR12|PDLI7   50 Human 0 3 
27 Annexin A5 (ANXA5) P08758|ANXA5   36 Human 0 3 
28 60S ribosomal protein L7a (RPL7A) P62424|RL7A   30 Human 0 3 
29 Dihydrolipoyl dehydrogenase, mitochondrial (DLD) P09622|DLDH   54 Human 0 3 
30 Band 4.1-like protein 2 (EPB41L2) O43491|E41L2   113 Human 0 3 
31 Filamin-B (FLNB) O75369|FLNB   278 Human 0 3 
32 3-hydroxyacyl-CoA dehydrogenase type-2 (HSD17B10) Q99714|HCD2   27 Human 0 3 
33 Ras GTPase-activating-like protein IQGAP1 (IQGAP1) P46940|IQGA1   189 Human 2 34 
34 Coronin-1C (CORO1C) Q9ULV4|COR1C   53 Human 2 18 
35 Filamin-A (FLNA) P21333|FLNA   281 Human 3 14 
36 Tropomyosin alpha-3 chain (TPM3) P06753|TPM3   33 Human 1 14 
37 
Serine/threonine-protein phosphatase PP1-gamma 
catalytic subunit (PPP1CC) P36873|PP1G   37 Human 1 14 
38 Cytospin-A (CYTSA) Q69YQ0|CYTSA   125 Human 1 13 
39 
Protein phosphatase 1 regulatory subunit 12A 
(PPP1R12A) O14974|MYPT1   115 Human 2 10 
40 Nexilin (NEXN) Q0ZGT2|NEXN   81 Human 2 6 
41 40S ribosomal protein S3 (RPS3) P23396|RS3   27 Human 1 8 
42 Cytospin-B (CYTSB) Q5M775|CYTSB   119 Human 1 5 
43 78   glucose-regulated protein (HSPA5) P11021|GRP78   72 Human 1 7 
44 Nucleolin (NCL) P19338|NUCL   77 Human 1 5 
45 L-lactate dehydrogenase A chain (LDHA) P00338|LDHA   37 Human 1 5 
46 40S ribosomal protein S4, X isoform (RPS4X) P62701|RS4X   30 Human 1 5 
47 Tropomyosin alpha-4 chain (TPM4) P67936|TPM4   29 Human 1 4 
48 Cell division control protein 2 homolog (CDC2) P06493|CDC2   34 Human 1 4 
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49 40S ribosomal protein S2 (RPS2) P15880|RS2   31 Human 1 4 
50 Supervillin (SVIL) O95425|SVIL   248 Human 1 4 
51 14-3-3 protein theta (YWHAQ) P27348|1433T    28 Human 1 3 
52 Spectrin alpha chain, brain (SPTAN1) Q13813|SPTA2   285 Human 34 93 
53 Alpha-actinin-4 (ACTN4) O43707|ACTN4 105 Human 37 91 
54 Alpha-actinin-1 (ACTN1) P12814|ACTN1 103 Human 19 39 
55 Spectrin beta chain, brain 1 (SPTBN1) Q01082|SPTB2   275 Human 10 34 
56 Myosin-Ic (MYO1C) O00159|MYO1C    122 Human 16 34 
57 Myosin-Ib (MYO1B) O43795|MYO1B   132 Human 13 31 
58 Myosin phosphatase Rho-interacting protein (MPRIP) Q6WCQ1|MPRIP   117 Human 11 29 
59 LIM domain and actin-binding protein 1 (LIMA1) Q9UHB6|LIMA1   85 Human 6 18 
60 Uncharacterized protein C19orf21 Q8IVT2|CS021    75 Human 6 15 
61 Protein flightless-1 homolog (FLII) Q13045|FLII    145 Human 4 10 
62 
ATPase family AAA domain-containing protein 3A 
(ATAD3A) Q9NVI7|ATD3A    71 Human 2 5 
63 F-actin-capping protein subunit beta (CAPZB) P47756|CAPZB    31 Human 2 5 
 
*Results shown are from GFP and GFP-TepP IP using GFP-Trap, followed by mass spectrometry analysis. 
*Proteins identified with less than 3 unique spectra or found to be less than 2 fold more abundant than in control GFP samples    
were not included.  
aUnique spectrum: Two spectra are unique if they match different peptides (even if the peptides overlap), or if they match two 
different charge states of the same peptide, or different modified forms of the same peptide.  
bAccession number for NCBI 
 
4.3.9 TepP induces cell morphology changes after Chlamydia infection 
The results described thus far address the potential functions of TepP during infection 
on a molecular level. To get a broader view of functions on a cellular level, we decided to look at 
cell morphology after infection. Confluent A2EN cells were infected with either CTL2-
M062G1+pV or CTL2-M062G1+pTepP with an MOI of 50. Surprisingly, cells started to clump 
together and form ‘islands’ within 1 hpi after infected with complement strain; whereas the cells 
infected with tepP-deficient mutant had morphology similar to uninfected cells (Fig 21A). 
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Immunoblot analysis of samples collected at later time point (8 hpi) showed no difference in 
global actin levels (Fig 21B), suggesting that the observed space between cells was not due to 
cell loss but cell structural changes. Interestingly, this morphology changes were not apparent in 
HeLa cells or Vero cells and did not happen when using MOI less than 10 (data not shown), 
indicating that this morphology change is evident in cell lines with architecture closer to the 
natural context of infection.  
 
Figure 21: TepP-induced cell morphology changes. A) A2EN epithelial cells were infected with 
CTL2-M062G1 transformed with empty vector (Vec) and vector containing wild type tepP gene 
(pTepP) at an MOI of 50.  Cell clumping was observed in cells infected with complement strain, 
whereas cells infected with mutant strain showed no difference from uninfected cells.  Images 
were acquired by differential interference contrast (DIC) after 1 hpi. B) Total actin levels did not 
change between cell monolayers infected with mutant and complemented strains. A2EN 
epithelial cells were infected as in (A). Protein samples were collected at 8 hpi and analyzed by 
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immunoblot with antibodies against TepP, MOMP and Actin. Actin is a loading control for host 
cell and MOMP is a loading control for bacteria. 
 
Figure 22: Model of the regulation and function of early effectors in signaling events occurring 
during the establishment of a nascent Chlamydia inclusion. The EB form of C. trachomatis is 
pre-loaded with multiple T3S effectors and chaperones. The majority of TARP and Ct694, two 
known early effectors, are pre-complexed with their cognate chaperone, Slc1, whereas only a 
small portion of TepP is in complex with Slc1. Upon Chlamydia attachment, TARP and Ct694 are 
translocated into host cell cytoplasm, freeing Slc1 to associate with TepP and enhance its 
secretion. TepP is translocated across membranes and phosphorylated by host tyrosine kinases. 
Phospho-TepP then recruits the host scaffolding protein, Crk, through interacting with the SH2 
domain of Crk. The SH3 domain of Crk then recruits other host proteins to the nascent inclusion 
to initiate signaling cascades within the infected cell. TepP may also recruit additional proteins 
to initiate signaling responses independent of Crk. 
 
4.4 Discussion 
Our findings indicate that TepP is a novel C. trachomatis effector that is targeted for 
tyrosine phosphorylation upon delivery into epithelial cells.  TepP is phosphorylated at both 
tyrosine and serine residues (Fig. 14 and Fig. 15A), with a phosphotyrosine residue mapping to 
the peptide ASDYDLPR, which is repeated in tandem between amino acids 496-504.  This 
phosphorylation site matches the pYxxP consensus binding site for the host adaptor proteins 
 96 
Crk-I and Crk-II (Songyang et al., 1993). Indeed, we found that both Crk proteins co-IP with 
endogenous TepP during the early stages of EB infection (Fig. 15B). This interaction is likely to be 
direct and dependent on tyrosine phosphorylation since recombinant TepP only interacts with 
GST-CrK upon in vitro phosphorylation (Fig. 15D).  Consistent with these observations, CrkI-II 
associated with EBs at entry sites and nascent inclusions (Fig. 15C). Importantly, the lack of CrkI-
II association with nascent inclusions in a tepP null mutant strain and restoration after 
complementation provided genetic confirmation that TepP is required for Crk recruitment.  
CrkI-II are well-characterized scaffolding proteins that organize cytoskeletal 
rearrangement and signal transduction events (Birge et al., 2009).  The SH2 domain of Crk 
interacts with tyrosine-phosphorylated proteins. The SH3 domain, in turn, can interacts with 
multiple proteins including guanine nucleotide exchange factors (GEFs) such as C3G, Sos1 and 
Dock180, and c-Abl and PI3K (p85 subunit), a protein and lipid kinase (reviewed in (Birge et al., 
2009)). The manipulation of Crk function by bacterial effectors is not unprecedented.  In 
Helicobactor pylori, CagA, a Type IV secretion effector, is tyrosine-phosphorylated upon 
translocation and interacts with Crk (Suzuki et al., 2005).  This interaction then triggers 
downstream signaling events of Crk, including SoS1/H-Ras/Raf1, C3G/Rap1/B-Raf and 
Dock180/ELMO pathway, resulting in CagA-specific cell responses such as epithelial cell 
scattering and cell-cell dissociation (Suzuki et al., 2005).  In Pseudomonas aeruginosa, 
exoenzyme T (ExoT) ADP-ribosylates both CrkI and CrkII, preventing the binding of Crk SH2 
domain to focal adhesion complex proteins, paxillin and p130cas (Deng, Sun, & Barbieri, 2005).  
This leads to uncoupling of integrin signaling and results in actin depolymerization and 
potentially contributes to the anti-phagocytic activity of this opportunistic pathogen. The 
function of Crk in C. trachomatis infection is less clear.  Because the Crk partner Sos1 and 
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Dock180 activate Rac1 (Kiyokawa et al., 1998; Nimnual, Yatsula, & Bar-Sagi, 1998) and Rac1 
activation is partially required for C. trachomatis invasion (Carabeo, Grieshaber, Hasenkrug, 
Dooley, & Hackstadt, 2004), it is possible that TepP, in addition to TARP (Lane et al., 2008), 
contributes to Rac1 activation at bacteria entry sites through its recruitment of Crk.   However, 
since TepP is not essential for bacterial entry or establishment of the replicative vacuole within 
epithelial cells (Fig. 19D), we see a limited role for this effector in the activation of these 
pathways.  Similarly, RNAi-mediated silencing of CrkI-II in HeLa cells did not affect the ability of 
bacteria to enter and replicate in these cells (Fig. 19A-C).  These findings are in contrast to 
observations made in Drosophila S2 cells where Crk was identified as a potential host factor 
important for C. muridarum growth (Elwell, Ceesay, Kim, Kalman, & Engel, 2008), and suggest 
possible differences in cell lines or Chlamydia strains used.  At this stage we do not know the full 
compendium of proteins recruited to nascent inclusions via TepP and Crk-mediated protein 
scaffolding. However, it is clear from the number of proteins that are tyrosine-phosphorylated in 
a TepP-dependent manner that TepP contributes to multiple signaling events during Chlamydia 
invasion. 
 
Since signaling events often lead to changes in gene transcription, we performed a 
microarray analysis to compare the global transcript level response of A2EN cells to infection 
with tepP mutants versus their complemented counterparts.  Interestingly, many immune-
related genes showed a TepP- dependent activation.  Among them, the most striking changes 
were observed for IFIT1 and IFIT2 with a fold-change more than 10 fold by 8 hpi (Fig. 20C).  IFIT1 
and IFIT2 belong to a family of interferon-induced protein with tetratricopeptide repeats (IFITs) 
that have a well-established role in host anti-viral defense.  IFIT proteins repress the translation 
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of viral genes by binding to eIF3, a translation initiation factor, and virus RNA bearing 5’-
triphosphate, leading to suppression of virus replication (Hui, Terenzi, Merrick, & Sen, 2005; 
Pichlmair et al., 2011; Terenzi, Hui, Merrick, & Sen, 2006).  In addition, ectopic overexpression of 
IFIT2 promotes cell death by a mitochondrial pathway, revealing another potential anti-viral 
mechanism for these proteins (Stawowczyk, Van Scoy, Kumar, & Reich, 2011).  The role of IFIT 
proteins in bacterial infections is less clear.  In murine macrophages, overexpression of IFIT2 
represses lipopolysaccharide (LPS) induced TNF- α and IL-6 expression (Berchtold et al., 2008).  
In contrast, IFIT2-/- mice display reduced TNF- α and IL-6 in serum and LPS-mediated lethality in 
an endotoxic shock model, suggesting IFIT2 is a critical mediator for the secretion of LPS-induced 
proinflammatory cytokines (Siegfried et al., 2013).  In C. trachomatis, both IFIT1 and IFIT2 genes 
were reported to be up-regulated more than 10-fold in HeLa 229 cells by 16 hpi (Lad, Fukuda, Li, 
de la Maza, & Li, 2005).  Our study shows that in the absence of TepP, the transcript level of 
IFIT1 and IFIT2 is similar to the level of uninfected A2EN cells, implying that TepP-mediated 
signaling regulates the expression of these genes during C. trachomatis infection.  IFIT1 and IFIT2 
can be induced directly by type I interferon (IFN -α/β) (Der, Zhou, Williams, & Silverman, 1998). 
In addition, binding of host pattern recognition receptors (PRRs), including Toll-like receptors, 
retinoic acid-inducible gene I-like receptors, and DNA-dependent activators of IRFs, to the 
microbial nucleic acids and other macromolecules, such as LPS, could also induce transcription 
of IFIT1/2 IFIT1 (Reich, 2013). Since Chlamydia infection induces type I IFN secretion in host cells, 
either Chlamydia-induced IFN or Chlamydia LPS or both may contribute to this up-regulation. 
We are currently investigating what TepP-mediated signal transduction pathways may mediate 
the change of IFIT transcripts and other genes early in infection and the consequences of these 
events in colonization of the host. 
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In addition to the effects in molecular levels, TepP is also responsible for a drastic cell 
morphology change induced by Chlamydia infection (Fig. 21). This phenomenon only happens 
when using high MOI, which may not be the case during the primary infection within the host. 
However, during secondary infections, when newly-generated EBs are released from infected 
cells, the surrounding cells will be exposed to a relatively high amount of Chlamydia – effectively 
a high MOI. We hypothesize that this destruction of cell monolayers may help Chlamydia 
dissemination in the genital tract because Chlamydia could better access cells in deeper layers 
when upper monolayers are destroyed. This destruction is likely to be mediated by the actin-
remodeling potential of TepP. Nevertheless, this hypothesis will require further animal 
experiments to support. 
 
Taken together, our data is consistent with a model in which TepP acts as a scaffolding 
protein that upon tyrosine phosphorylation, recruits additional scaffolding proteins like Crk, 
which in turn recruit more proteins to nascent inclusions, presumably to help establish an early 
niche for replication within the host (Fig. 22). In addition, the transcriptional response of host 
cells to infection with tepP mutants suggest that there is a distinct gene expression program that 
is dependent on TepP-mediated signaling events.  We hypothesize that the compendium of 
genes activated and repressed in a TepP-dependent manner are important in establishing an 
immune environment within infected tissues that is more conducive to C. trachomatis 
colonization, survival and/or dissemination. 
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5. Concluding remarks 
Despite the immense health cost burden associated with Chlamydia infections, little is 
known about its pathogenesis. Our understanding of the mechanisms that drive pathogenesis is 
limited by the dearth of molecular genetic tools available for manipulating chlamydial genomes 
and its complex parasitic and biphasic developmental cycle.  Approximately 5-10% of the C. 
trachomatis genome is predicted to encode proteins with putative T3S signals (Arnold et al., 
2009; Samudrala et al., 2009).  These potential effector proteins are presumably translocated 
into host epithelial cells at various stages of infection to mediate epithelial cell invasion, 
establishment of a protected replicative vacuole, and evasion of innate immune responses 
(reviewed in (Betts et al., 2009)).  Because Chlamydia cannot be readily manipulated with 
molecular genetic tools, most approaches for identifying effectors have been indirect and relied 
on heterologous expression systems (Valdivia, 2008). To date, only two effectors that are 
secreted in the early stage of infection, TARP and Ct694, have been experimentally validated in 
C. trachomatis (Clifton et al., 2004; Hower et al., 2009). Given the complexity of interactions 
with the host cell during Chlamydia entry and nascent inclusion development, we expected 
additional effectors to be secreted upon the association of the EB with its target epithelial cell 
and that most of these effectors are pre-loaded in EBs.  Indeed, a quantitative analysis of the C. 
trachomatis EB proteome (Saka et al., 2011) suggested the presence of at least 20 abundant 
hypothetical proteins with putative T3S signals.  EBs are also pre-loaded with most of the 
predicted T3S chaperones encoded by the Chlamydia genome.  However, putative T3S effectors 
are in molar excess to that of available T3S chaperones, which led us to speculate that these 
chaperones may engage multiple effectors. Indeed, by coupling immunoprecipitation of these 
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chaperones in EBs with mass spectrometry, we identified several potential T3S effectors that 
may function early during infection.  We further showed that one of the candidates, Ct875 
(TepP), is a T3S effector that is secreted early during Chlamydia infection.  A similar 
methodology may be applied to identify potential T3S effector in pathogens that are not 
genetically tractable. 
 
Usurping host cellular signaling pathways by effector tyrosine phosphorylation is an 
emerging theme among bacterial pathogens. Examples have been found in Enteropathogenic 
Escherichia coli, Helicobactor pylori and Bartonella henselae and the list is still growing (Backert 
& Selbach, 2005). Since protein tyrosine phosphorylation often results in recruitment of SH2 (Src 
homology 2) and PTB (phosphotyrosine binding) domains containing proteins and initiates 
signaling cascades in eukaryotes, Chlamydia may develop multiple strategies to exploit this 
pathway to recruits different layers of host proteins during infection. Indeed, Chlamydia 
infection induces multiple protein tyrosine-phosphorylations at early stage of infection 
(Birkelund et al., 1994; Fawaz et al., 1997).  Nevertheless, only two proteins, TARP (Clifton et al., 
2004) and Ezrin (Swanson et al., 2007) have been experimentally validated so far. Our study 
identified the third one, TepP (Ct875).  Interestingly, cells infected with a TepP mutant strain 
only elicits phosphorylation of the 150 kDa protein, which is TARP, suggesting TepP is the critical 
mediator of the other phosphorylation events.  Future direction can be aimed at addressing the 
identities of these proteins and host signaling events they may target 
 
In the battlefield between pathogen and host, using the right weapon at the right time is 
the key to succeed. The temporal manner in which effectors are secreted is likely to be 
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important for the proper manipulation of host cell functions.  This is especially vital for an 
obligate intracellular pathogen like Chlamydia, whose propagation is entirely reliant on host 
cells. However, how the hierarchy of effector secretion is determined remains a mystery. One 
possibility is that the regulation relies on the transcription and translation of T3S effector and 
the apparatus transport whatever is available. The other possibility is that bacterial regulatory 
proteins shuttle destined cargo to secretion apparatuses at the correct time. In the later 
hypothesis, it is likely that chaperones provide this regulatory function. In Chlamydia, both Mcsc 
and Slc1 are classified as class IB chaperones and bind multiple effectors. In both cases, we 
observed a differential binding preference of these chaperones to their cognate cargos, 
suggesting a hierarchy in effector translocation that may be partially imparted by chaperone. In 
the case of Mcsc, it binds to three inclusion membrane proteins with an order of affinity 
reversely correlated to the timing of their protein expressions.  This strategy may ensure that 
late expressed effectors can be secreted in a timely manner and exert their functions (Fig. 7). 
   
At the EB stage, the majority of TARP and Ct694 are found pre-complexed with Slc1, 
whereas only a minor portion of TepP is present in complexes with Slc1 (Fig. 9), even though 
TepP is more abundant than TARP and Ct694 in EBs (Saka et al., 2011).  This implies that this 
pre-engagement with its chaperone could prime Tarp and Ct694 for rapid secretion upon 
attachment.   Given these observations, we considered a model wherein T3S substrates pre-
bound by Slc1 in EBs, such as TARP and Ct694, will be delivered first, followed by TepP and 
potentially others effectors which do not exist as pre-formed chaperone complexes in EBs.  
Consistent with this model, TepP was tyrosine-phosphorylated later than TARP (Fig. 13D).  
Although we cannot exclude the possibility that TepP-specific tyrosine kinases are recruited later 
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than those that phosphorylate TARP, our preliminary results indicate that TepP is 
phosphorylated by kinases that also target TARP (Victoria Carpenter, unpublished data), making 
this possibility less likely.  Overall, the delayed phosphorylation of TepP, coupled with the 
relative abundance of Slc1-Tarp as compared to Slc1-TepP complexes within EBs lead us to 
propose that Slc1 imparts a hierarchy to the translocation of effectors during Chlamydia 
invasion (Fig. 22). Since many T3S components are conserved among many pathogenic Gram-
negative bacteria, including Yersinia, Salmonella and Shigella species (Cornelis, 2006), T3S 
systems might share an evolutionarily conserved mechanism. Therefore, this study on the 
chlamydial T3S system may also be applicable to the T3S systems in these pathogens and might 
help develop better strategies for treatment.  
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Appendix 1: Plasmid constructs used in this study. 
Vector Insert 
Yeast two Hybrid   
pGBT9  
Cap1(Ct529)(1-254 a.a.)(1-20 a.a.)(1-50 a.a.) (1-100 
a.a.)(100-176 a.a.)(100-224 a.a.)(176-224 a.a.) 
pGBT9 
Ct618(1-214 a.a.)(1-20 a.a.)(1-50 a.a.) (1-100 
a.a.)(100-140 a.a.)(100-193 a.a.)(140-193 a.a.) 
pGAD424 Mcsc(FL) (Ct260) 
  
Crystallography   
pET30-GBFusion1 (pGBF1OPT)/TEV  Cap1(176-224 a.a.) 
pET30-GBFusion3 (pGBF3OPT)/TEV  Ct618(140-193 a.a.) 
pET30-GBFusion3 (pGBF3OPT)/TEV Ct225(69-122 a.a.) 
  
In vivo stability/secretion assay   
p2TK2-SW2  WTCap1 (1-224 a.a.)-GSK 
p2TK2-SW2 H188ACap1 (1-224 a.a.)-GSK 
p2TK2-SW2 H188DCap1 (1-224 a.a.)-GSK 
p2TK2-SW2 WTCt618 (1-214 a.a.)-GSK 
p2TK2-SW2 H156ACt618 (1-214 a.a.)-GSK 
p2TK2-SW2 H156DCt618 (1-214 a.a.)-GSK 
  
Yersinia T3S system    
pBAD24  Mcsc(FL) 
pBAD24  Slc1(FL) 
pBAD33 Ct694 (FL) 
pBAD33 Ct695(FL)-FLAG 
pBAD33 TepP(FL) (Ct875) 
  























  Slc1/TepP(FL)-6His 
  
Chlamydia Transformation   
p2TK2-SW2 TepP(FL) 
   
*FL-full length 
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Appendix 2: Primer sequences used for Q-PCR  
    
Primer Sequence (5' - 3') 
  IL-6 Forward gatgagtacaaaagtcctgatcca 
IL-6 Reverse ctgcagccactggttctgt 
CXCL3 Forward aaatcatcgaaaagatactgaacaag 
CXCL3 Reverse ggtaagggcagggaccac 
MAP3k8 Forward cgcaagaggctgctgagt 
MAP3k8 Reverse ttcctgtgcacgaagaatca 
IFIT1 Forward agccagatctcagaggagcc 
IFIT1 Reverse ccatttgtactcatggttgctgtaa 
IFIT2 Forward tggtggcagaagaggaagat 
IFIT2 Reverse gtaggctgctctccaaggaa 
Actin Forward ccaaccgcgagaagatga 
Actin Reverse ccagaggcgtacagggatag 
16S rRNA Forward ggaggctgcagtcgagaatct 
16S rRNA Reverse ttacaaccctagagccttcatcaca 
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